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Abstract 
HIV Antiretroviral Treatment Adherence  
and Its Impact on  
HIV Disease Indicators  
in the US Military HIV Natural History Cohort Study 
 
 
 
 
Background: Treatment or medication adherence is an important factor in improving 
HIV disease indicators among HIV-infected patients. Among members of the US Military 
HIV Natural History Cohort Study (NHS), we compared self-report and pharmacy-based 
refill adherence measures and evaluated their association to HIV disease indicators (HIV 
RNA viral load and CD4 counts).   
 
Methods: Self-report adherence data was retrieved for 1572 individuals from the NHS 
cohort during 2006-2010 while pharmacy-based refill data was collected from 2005-
2009 for 1458 NHS study participants to create pharmacy-based refill adherence 
measures (proportion of days covered).  Adherence measures and repeated measures of 
HIV RNA viral load and CD4 counts were analyzed using a mixed effect model to 
evaluate whether antiretroviral adherence impacted disease progression in this cohort.  
Race/ethnicity and depressive symptoms (CESD < 16, CES >=16) were included in the 
final model to assess their respective mediating effects on antiretroviral adherence and 
HIV disease indicators.  Self-report and pharmacy-based refill adherence measures were 
compared using Cohen’s Kappa.  Chi Square test was administered to detect differences 
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in responses between African Americans (AA) and European Americans (EA) for reasons 
for missed doses (barriers to treatment adherence).   
 
Results: Level of agreement in identifying optimal adherers (>=90%) was low between 
self-report and pharmacy-based refill measures (Cohen’s Kappa: 0.05).  Using self-report 
adherence in the mixed effects models resulted in a decrease of 0.14 log viral load and 
an increase of 8.8 cells/mm3 CD4 count for every 10% increase in adherence.  Pharmacy-
based refill adherence was not associated with HIV RNA viral load.  Race/ethnicity was 
an independent predictor for viral load with AA having an increase of 0.09 log viral load 
compared to EA keeping other covariates constant.  Depressive symptoms were not 
significantly associated with HIV RNA viral load after adjustment.  Chi square tests were 
significant in detecting race differences (between AA and EA) for the majority of reasons 
for missed doses (barriers to adherence).   
 
Conclusions: Self-reported adherence was significantly associated with HIV RNA viral 
load and CD4 counts.  The mediating effect of race (AA) was significant in evaluating the 
association between treatment adherence and HIV RNA viral load.  AA reported more 
barriers to treatment adherence in comparison to EA in this cohort. 
 
   
 
  
1 
 
1 BACKGROUND AND LITERATURE REVIEW 
1.1 Approaches to HIV Antiretroviral Treatment and the Role of Medication 
Adherence 
 
Advances in HIV treatment, particularly highly active antiretroviral treatment 
(HAART), have resulted in a reduction in morbidity and mortality due to HIV while 
extending and improving quality of life among HIV positive patients.  Effectiveness of 
antiretroviral therapy in reducing HIV RNA viral load in multiple studies led some 
researchers to conclude that treatment could not only reduce virologic outcomes, but 
potentially also dually serve as a prevention strategy in reducing HIV transmission and 
the number of new HIV infections.  In the HPTN 052 study, early initiation of 
antiretroviral treatment was shown to reduce HIV transmission by 96% for HIV infected 
“treated” individuals (with CD4 cell count between 350 and 550 cells/mm3) to their 
respective uninfected partners compared to serodiscordant couples whose treatment of 
the HIV infected partner was delayed.[1]  The study was halted immediately by the Data 
and Safety Managing Board upon these findings.  These conclusions gave rise to 
“treatment as prevention” or “test and treat” strategies shifting HIV prevention efforts 
towards the ramping up of early initiation of antiretroviral treatment.  “Test and treat” 
strategies are highly dependent on the proper diagnosis of HIV infected individuals 
accompanied by expedient administration and initiation of antiretroviral therapy.  
Success of this strategy is predicated on HIV infected individuals having access to 
antiretroviral therapy while being consistently and highly adherent to prescribed 
therapy. 
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While acknowledging the effectiveness of antiretroviral (ART) therapy in 
combatting HIV transmission, others theorized that poor engagement in care of HIV 
infected individuals would limit “test and treat” strategic goals in reducing HIV 
transmission.[2]  Gardner, et al. identified that despite over 15 years availability of 
HAART as well as the introduction of single-pill, fixed-dose combination drugs, only 19% 
or approximately 1.1 million HIV-infected individuals had an undetectable HIV-1 RNA 
viral load.[3]  While the authors acknowledged these numbers as estimates, their 
conclusion underscores the importance of a multifaceted approach to successfully 
maintain virologic suppression in HIV-infected populations.  The authors defined the HIV 
care of continuum (also known as the HIV treatment cascade) as having the following 
stages of engagement in HIV care: a diagnosis of HIV infection, linkage to care, retention 
in care, receipt of antiretroviral therapy, and achievement of viral suppression.[3]     
 
Recent guidelines and recommendations by CDC and federal/state health 
agencies have given credence to this model with the launch of the HIV Care Continuum 
Initiative in 2013.  The major steps along the continuum similarly follow the steps 
outlined in the Gardner, et al. model   with concrete goals to gather data about and 
increase the proportion of individuals within each step:  
1) diagnosed with HIV infection,  
2) linked to HIV medical care,  
3) engaged in HIV medical care,  
4) prescribed ART, and  
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5) virally suppressed.   
 
Data from this recent CDC MMWR report showed that of the 1.2 million US HIV-
infected individuals in 2011, approximately 37% were prescribed antiretroviral therapy 
while only 30% were virologically suppressed.[4]   
 
Regardless of the HIV antiretroviral treatment framework adopted (i.e. Test to 
Treat vs HIV Care Continuum, etc), all emphasize the importance of patient adherence 
to prescribed antiretroviral treatment.  Many studies have shown that patient 
adherence to HIV treatment is correlated with viral suppression and improved 
immunologic response.[5, 6]  Poor adherence has been correlated with the 
development of HIV resistant strains, worsening of virologic outcomes, and increased 
mortality.[7-13]  
 
1.2  Medication Adherence 
While medication adherence is essential to managing HIV, it is also relevant to 
many other conditions/diseases as well.  Adherence is generally defined as a patient’s 
conformance to taking medication as prescribed.  Rates of medication adherence are 
usually reported as the percentage of prescribed doses of medication taken by the 
patient over a specified interval or period of time.[14]  The measurement and impact of 
medication adherence on health outcomes continues to be a priority within other 
chronic disease domains such as cardiovascular disease and mental health.[15-18].  Each 
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condition may deal with different target populations with unique sets of risk factors.  In 
addition, adherence percentage levels to indicate proper therapeutic management will 
vary by condition and medication/intervention type.[14]  Interventions to improve 
adherence tend to be successful in single disease, short term settings.  However, 
patients with multiple chronic diseases requiring medication for extended durations 
require more robust and creative interventions to ensure high adherence over time.[18-
21] 
 
As HIV-infected individuals live longer, adherence to HIV antiretrovirals is 
essential to ensure improved health outcomes and quality of life.  While high rates of 
adherence levels (>95%) have historically been recommended to attain and maintain 
virologic suppression, multiple studies have shown the possibility of maintaining 
virologic suppression at lower levels of adherence.[22-24]   Conway, et al suggested that 
“that adherence levels as low as 60% can lead to the maintenance of virologic 
suppression but are clearly insufficient in the setting of active viral replication.”[23] 
Using a repeated measures longitudinal analysis, Liu, et al, demonstrated that 
undetectable viral load could be achieved with a wide range of adherence (80%-
95%).[24]  Maggioli, et al. proposed a cutoff of 85% to observe a 5.3%–23.5% reduction 
in the risk of virologic failure.  A possible explanation for the ability of certain patients to 
maintain virologic suppression with lower levels of adherence may be due to 
component/class differences within antiretroviral combination therapy.  Many studies 
identified different adherence cutoffs between non-nucleoside reverse transcriptase 
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inhibitors (NNRTIs) versus Protease Inhibitor (PIs).  The long half-life of NNRTIs may 
allow it to persist in the blood even after several days of nonadherence resulting in 
partial therapeutic benefit.[22] In contrast, for PIs, the >95% adherence cutoff was 
derived from many studies where the older PI-based regimens without boosting were 
used.  Nelson, et al. reported that out of 929 veterans, only 19.7% of PI patients had 
proportion of days covered (PDC)>80% compared to 35.1% of NNRTI patients.[25]  With 
increased potency and decreased toxicity of HAART, mean adherence levels required to 
maintain virologic suppression will lower over time.  Despite the possibility of lower 
acceptable thresholds for adherence due to improvements to HAART, non-HAART 
related barriers and factors correlated to poor adherence should continue to be 
monitored.  
 
Studies from larger cohorts have shown stable levels or increased adherence 
over time.  Adherence among participants in the Royal Free Clinic Cohort did not 
decrease over a decade after starting HAART.  Cambiano, et al. attributed this to better 
tolerability of ART and clinical management, proactive switching of patients for reasons 
of toxicity, and patient awareness of the importance of adherence to long-term 
success.[26]  In a recent study among 21,865 HAART users from the Veterans Affairs 
(VA), Viswanathan, et al. reported that the proportion of virologically suppressed users 
with MPR>=95% increased marginally over time (2001-2010).  The increase was 
attributed to newer HAART regimens and less complex pill administration (e.g. once-
daily formulations with multi-dose regimens, single-pill fixed-dose combination, etc.)  
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The authors conclude that providers “should not let concerns regarding barriers to 
adherence hinder the prescription of newer HAART regimens at early stages of the 
disease.”[27]   
 
1.2.1  Overview of Medication Adherence Methods 
Medication adherence methods estimate the rate at which a patient is taking 
medications as prescribed.  Methods of adherence can be categorized as direct or 
indirect (see figure 1).   
 
 
Adherence 
Measurement 
Method  
Type Source of Data Strengths  Limitations 
Self-Report Indirect Questionnaire 
Simple, 
Validated, 
Economical  
Responses subject to 
recall bias, social 
desirability bias 
Pharmacy 
Refill 
Indirect 
PDTS 
(administrative 
medication 
database) 
Unobtrusive 
(no patient 
interaction), 
data driven 
Moderately expensive 
(cost of programming), 
documented 
dispense/refill data does 
not guarantee pill 
consumption 
compliance 
Pill Counts Indirect 
Medication 
counts; number 
of pills 
remained in 
bottle 
Clear, precise 
counts;  
Expensive, patient may 
misplace or discard pills 
Electronic 
Monitoring 
(caps) 
Indirect 
Electronic data 
captured via 
computer chip 
Objective, 
does not 
require staff 
monitoring 
Expensive (multiple 
caps), equipment failure 
possible 
Clinical 
observation 
Direct 
Direct 
observation 
Direct 
observation 
Expensive, pill may be 
hidden in mouth 
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Biomarkers Direct 
Bioassays/Urine
/Blood 
Easily 
detectable, 
Objective 
Expensive, influenced by 
other drugs, diet, etc., 
limited number of 
markers available 
Figure 1 - Adherence Measurement Methods 
 
 
 
Direct adherence measurement methods include clinical observations or the use 
of biomarkers.  For clinical observations, the patient is observed receiving and/or taking 
the medication.  For direct measurement using biomarkers, bioassays of urine or blood 
are frequently obtained.  Other methods include the use of drug markers with the target 
medication.  Direct methods, while easily detectable and accurate, tend to be 
expensive, limited/impractical, and burdensome to implement.   
 
Most adherence studies choose to incorporate indirect methods of adherence.  
Indirect measures include self-report, prescription or pharmacy refill, pill counts, and 
electronic monitoring (caps).  For self-report, adherence data is typically captured via 
interview, questionnaire, and or diary.  Self-report is the most popular method of 
capturing adherence information as it tends to be economical and both easier to 
administer and validate.  However, self-report also is subject to both recall (i.e. 
forgetting) and social desirability (i.e. tendency to give responses that the interviewer 
will find favorable) bias.[14]  Pill count is an objective method in which the number of 
pills is counted (i.e. number of pills remaining in the bottle).  The challenge with this 
method is that the patient could modify the adherence rate by removing or dumping 
pills before a scheduled visit.  Electronic monitoring can be performed using medication 
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event monitoring systems (MEMS) via microchips built into the caps.  This is an objective 
method that provides data that can be captured, downloaded, and analyzed 
electronically.  MEMS, however, tend to be expensive and equipment failure is a 
possibility.  While adherence is inferred, the opening and closing of medication bottle 
caps do not provide definitive evidence that pills are being ingested.   Pharmacy refill or 
claims is a data-driven process that requires access to pharmacy administrative claims 
information.  This method is unobtrusive and does not require patient interaction to 
obtain the data.  Pharmacy dispense/refill information assumes, but cannot verify actual 
medication ingestion/adherence.  Data completeness is also dependent on where 
patients go to fill their prescriptions and whether all transactions and fill records are 
accessible.  The choice of method depends largely on the resources available, purpose, 
and particular goal/use of the data.     
 
1.2.2  Self-Report and Pharmacy-based Refill Methods 
Strengths and weaknesses of adherence measurement approaches have been 
well cited and have been implemented and validated in multiple studies.[7, 28-45]  Of all 
the adherence methods, self-report has been most widely implemented for the reasons 
described earlier.  Walsh, et al. demonstrated the utility of a visual analogue scale (VAS) 
combined with a self-reported questionnaire Medication Assessment Self-Report 
Inventory (MASRI) to validly collect treatment adherence data in a visual manner.[7]  
The responses were compared to MEMS TrackCap (medication event monitoring 
system), pill count, and plasma HIV viral load to assess level of agreement in measuring 
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treatment adherence.   Due to social desirability bias, self-reported responses often 
overestimate true adherence while having low sensitivity for detecting 
nonadherence.[32]  Despite these limitations, the majority of HIV self-report adherence 
studies correlate reasonably well with HIV RNA viral load and CD4 count.[42] In a 
review, Simoni, et al. found significant correlation between self-report adherence and 
viral load for the majority of studies with correlation ranging from 0.3 to 0.5.[36]  Self-
report questionnaires can also be customized to capture qualitative responses about 
reasons for nonadherence.  Follow up questions can be crafted to capture the degree in 
which certain factors impacted adherence such as forgetting to take medication or 
discontinuing medications due to side effects, etc.       
 
Several studies have also incorporated pharmacy-based refill as a viable source 
for measuring treatment adherence.[39-41]  Pharmacy-based refill data is accessible via 
administrative databases and tend to be objective as patients are unaware of being 
monitored (not subject to recall or social desirability bias, deception, etc.).[12, 43]  
Pharmacy-based refill methods have also been validated as correlated with virologic 
outcomes, although there is some variability in terms of which pharmacy-based 
measures (e.g. MPR, PDC) are used and how they have been defined/implemented.[39, 
40, 44]  While self-report and pharmacy-based refill have both individually been 
associated with virologic and immunologic response to treatment, correlation between 
the two have been inconsistent.  At an HIV clinic in Melbourne, Fairley, et al. reported 
correlation between self-report and pharmacy-based refill after long-term follow up.  
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Both methods demonstrated increased mean adherence over time and predicted 
suppression of viral load (<400 copies/mL) at >95% (pharmacy refill) and >97% (self-
report).  In contrast, Garber, et al. found concordance between self-report and other 
adherence methods to vary widely with depending on type of measure used.  Interview-
based self-report was less likely to be concordant with other adherence methods in 
comparison to diary or questionnaire.  When comparing self-report measures and 
pharmacy-based refill studies, concordance was split.[45]  In a review of pharmacy-
based refill measures and methods, McMahon, et al indicated that data supported 
pharmacy-based refill as being a better predictor of outcomes than self-report.  
However, they also reported mixed concordance when evaluating ten studies between 
self-report and pharmacy-based refill.[39]  Despite the number of successful 
implementations of adherence studies using both methods, concordance varies and is 
highly dependent on measure definitions, administration method (interview, VAS, 
MASRI for self-report), duration of follow-up, and pharmacy-based measurement types 
(e.g. MPR, PDC, etc.). 
 
1.2.3  Pharmacy-based Refill Measures of Adherence  
Two commonly used measures of pharmacy-based refill adherence include the 
medication possession ratio (MPR) and the proportion of days covered (PDC).  The most 
commonly cited measure to reflect pharmacy-based treatment adherence is the 
Medication Possession Ratio (MPR).  Although there are variations in the way it is 
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calculated, MPR can be generally viewed as the number of medication days supplied or 
prescribed / number of days in the interval (period).[39, 46, 47]  
 
Despite the popularity of the MPR, recent studies have suggested that PDC may 
be a preferred measure of pharmacy-based refill adherence.  Nau, et al. and Peterson, 
et al., identified that use of MPR may overestimate adherence due to the reliance of 
calculating days supply.[47, 48]  By picking up an additional medication refill early 
towards the end of an interval, the MPR will have an excess number of days supply 
reflected in the numerator resulting in an inflated MPR.   It is not uncommon to see 
MPR rates greater than 100%.  PDC measures the proportion of days covered 
(medication on hand) / number of eligible days in the interval (period).  The key is the 
focus on the number of days (versus days supplied) in the numerator.  Therefore, unlike 
MPR having an excess of meds does not inflate the PDC, as the measure is concerned 
with whether medication was received for that day (or period of days).  In the following 
section, more details are provided to illustrate this difference.  
 
1.2.4  Calculating the MPR and PDC for a single medication 
Using the example below (figure 2) by Leslie, et al., we assume there are 4 claims 
during a six-month period and each claim reflects a 30-day supply.[79]  Using the 
formula (total days of supply / number of days in the interval), the MPR would be (4 x 30 
days of supply) / 180 days = 66.7%.  In other MPR calculations, the denominator is not 
fixed to a specific “calendar” time interval, but parameters are instead defined by the 
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refill period.  A minimum of two refill dates are required to calculate the MPR 
denominator using the “refill” interval concept: difference between the first refill day 
and the last refill date plus remaining days of the last refill (last Rx date - first Rx date + 
last Rx days of supply).[49]  Recalculating the MPR using this definition would result in 
an adjustment to the MPR denominator: (4 x 30 days supply) / (Number of days 
between July 30 – Feb 21 + 30 days) = 120 / 130 = 92.3%.   
 
The more recent measure of adherence is the proportion of days covered (PDC).  
PDC is the proportion of days covered by medication / number of eligible days in the 
interval (period).  Whereas MPR is focused on the total days of supply as the numerator, 
PDC is focused on the actual days medication is on hand.  In the same Leslie, et al. 
example below, PDC is first measured against the number of days in the time interval 
(180 days of coverage).[50]  Since the patient picked up claim 4 a few days before claim 
3 medications run out, there is an overlap.  The overlap impacts PDC calculations, 
because the same medication cannot be double counted on a single day.  Given this 
scenario, it would appear that the patient is being penalized for picking up refill meds 
early.  Researchers resolved this problem by employing a shift (see Claim 4 shifted 
below) to remove the overlap and to ensure the patient gets credited for the entire 
claim 4.  Using the PDC definition with the shift in place, the PDC is 120/180=66.7%.  If 
the refill denominator is used (last Rx date - first Rx date + last Rx days of supply), then 
PDC is calculated as 120 / (Aug 6 – Apr 21 + 30 days) = 120/136 = 88.2% (slightly lower 
and more conservative estimate of adherence than the MPR = 92.3%) 
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Figure 2 - PDC example by Leslie et al.[79]  
 
 
 
When comparing, MPR vs PDC, Nau, et al. states that MPR and PDC should 
approximate each other when examining adherence to a single drug.  PDC will be a 
more conservative estimate of adherence for a class of medications that are prone to 
switching and multiple medications are administered within the same class.[48]   
 
1.2.5  Calculating the PDC for Concomitant Medication 
In the previous example, MPR and PDC were calculated based off the refill 
patterns of a single medication.  In practice, however, it may be important to calculate 
adherence rates based on two or more medications and/or an entire regimen.  In the 
following example (figure 3), PDC is calculated separately for two medications.  PDC can 
certainly be calculated individually for each therapy (PDCA= 120/180=67% and PDCB= 
120/180=67%).  However, if there is a need to measure adherence to a specific regimen, 
then the PDC calculation can be modified to require both medications to be present on 
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the same days.  In the example below, the time periods in purple reflect the agreement 
between therapies A and B during the specified timeline.  The PDCAB (proportion of days 
covered by regimen) for this stricter criteria is markedly lower at 72/180 = 40%.  The 
examples hopefully make it clear that there are different ways PDC can be defined, 
calculated, and implemented.    
 
 
 
Figure 3 - PDC concomitant medication example by Leslie et al.[79]  
 
 
 
1.3  Factors associated with adherence failure/nonadherence 
Despite the ample literature emphasizing the importance of treatment 
adherence to ensure improved outcomes, significant barriers to achieving adherence 
remain.  A number of factors have been associated with antiretroviral nonadherence:   
1. Medication related factors: adverse side effects, treatment fatigue, ARV 
class [22, 23, 51, 52]; 
2. Health-related factors: comorbidities, psychosocial issues [53-57]; 
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3. Social constructs: homelessness, lack of access to treatment, discrimination 
[58-62];  
4. Personal factors: age, race, gender, education and literacy levels [63-68];  
5. Behavioral factors:  injection drug use, alcohol, multiple sex partners [69-75]  
 
Those burdened by social constructs tend to struggle with other factors as well.  
Some of the unique advantages of working with a predominately military population 
include the fact that patients have free access to healthcare, majority have a minimum 
of a high school education (or equivalent), are less likely to inject drugs (active duty 
subject to random drug testing), and are subject to mandatory  HIV screening.[76, 77]  
Use of the NHS study population therefore can be theorized as a “natural” adjustment 
of mediating factors (e.g. access to care, cost of medications, etc.) that often distort 
measures of associations reported in other studies. 
 
Barriers to adherence are multi-factorial.  Gifford et al identified that being busy 
or forgetting to take medications as the primary reason for missed doses.  However, 
other reasons related to logistics, change in routine, medication tolerability issues, 
depression, and other mental heath issues also can result in nonadherence.[78] 
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Figure 4 – Barriers to Adherence from Gifford et al.[78] 
 
 
 
1.4 Specific Aims 
The aims of this study are: 
Aim 1 – To identify and evaluate three potential adherence measures: self-report, 
pharmacy-based refill (standard antiretroviral regimen), and pharmacy-based refill (any 
single antiretroviral) and their respective relationships to HIV disease indicators (e.g. 
change to HIV RNA viral load and CD4 T-lymphocyte count) over time among members 
enrolled in the US Military HIV Natural History Study (NHS).   
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Aim 2a - To assess potential racial differences in HIV Treatment adherence and its 
association with HIV disease indicators between African Americans and European 
Americans in the NHS.  To explore potential racial differences in reporting reasons for 
missing doses (nonadherence factors).   
 
Aim 2b - To evaluate longitudinally the association between depression symptoms (CES-
D scale) and treatment adherence among members of the NHS.   
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2.  EVALUATION OF ADHERENCE MEASURES AND THEIR IMPACT ON HIV DISEASE 
INDICATORS 
 
2.1  Overview 
It is widely recognized that treatment or medication adherence is an important 
factor in achieving virologic suppression among HIV infected patients.  Previous studies 
identified the need to describe and measure treatment adherence among members of 
the US Military HIV Natural History Cohort Study (NHS), a multi-center HIV open 
enrollment cohort consisting of military members and beneficiaries.  The objectives of 
this aim are to 1) develop, describe, and evaluate three potential adherence measures: 
self-report, pharmacy refill (standard antiretroviral regimen), and pharmacy refill (any 
single antiretroviral) and 2) evaluate their respective relationships to HIV disease 
indicators (e.g. change to HIV RNA viral load and CD4 T-lymphocyte count) over time 
among members enrolled in the NHS.   
 
2.2 Background and Military Relevance 
Bosworth, et al. stated that “a major deficiency has been the inability to 
routinely measure and track adherence in standard practice.”[1]  Developing valid, 
reliable measure(s) of adherence for the military HIV-infected population is not only 
important from a clinical standpoint (i.e. HIV Treatment Care), but also is needed for 
research purposes.  Several sub-studies exploring HAART initiation, outcomes, and racial 
disparities among the NHS cohort have been published.  Weintrob, et al identified 
virologic differences between NHS blacks (AA) and whites (EA) after HAART initiation (6 
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and 12 months), but could not rule out adherence differences as the potential reason 
for the observed association.   In a study of clinical outcomes, Marconi, et al. reported a 
high cross sectional percentage (> 90%) of NHS individuals (1090) reporting > 90% 
adherence to prescribed treatment medication.  Potential factors contributing to high 
adherence patterns among the active duty population were qualitatively described, 
however they were unable to formally investigate its impact due to the limited 
adherence data available at that time.   Silverberg, et al. reported that African-
Americans in the NHS cohort had better disease outcomes when compared to European 
Americans during the pre-HAART era that was no longer evident after the introduction 
of HAART.[2]  Silverberg hypothesized that the change in trend (disease outcomes by 
race) after the introduction to HAART may have been due to reduced utilization of 
HAART among African Americans (cited other studies reporting lower odds of receipt of 
HAART as well as lower long-term adherence to HAART among African Americans).  As 
new research questions emerge, it would be beneficial to have measureable, validated 
medication adherence data available to researchers for future studies.   From a clinical 
standpoint, standard and systematic methods to measure and monitor antiretroviral 
adherence among the military HIV infected population could provide clinicians 
actionable information and potentially tools to actively engage HIV infected patients on 
issues related to nonadherence as outlined by Gardner, et al and the subsequent HIV 
Continuum of Care model.[3]   
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2.3 Adherence Measures Methods 
Strengths and weaknesses of adherence measurement approaches have been 
well cited and have been implemented and validated in multiple studies.[4-22]  Of all 
the adherence methods, self-report has been most widely implemented for the reasons 
described earlier.  Walsh, et al. demonstrated the utility of a visual analogue scale (VAS) 
combined with a self-reported questionnaire Medication Assessment Self-Report 
Inventory (MASRI) to validly collect treatment adherence data in a visual manner.[4]  
The responses were compared to MEMS TrackCap (medication event monitoring 
system), pill count, and plasma HIV viral load to assess level of agreement in measuring 
treatment adherence.   Due to social desirability bias, self-reported responses often 
overestimate true adherence while having low sensitivity for detecting 
nonadherence.[9]  Despite these limitations, the majority of HIV self-report adherence 
studies correlate reasonably well with HIV RNA viral load and CD4 count.[19] In a 
review, Simoni, et al. found significant correlation between self-report adherence and 
viral load for the majority of studies with correlation ranging from 0.3 to 0.5.[13]  Self-
report questionnaires can also be customized to capture qualitative responses about 
reasons for nonadherence.  Follow up questions can be crafted to capture the degree in 
which certain factors impacted adherence such as forgetting to take medication or 
discontinuing medications due to side effects, etc.       
 
Several studies have also incorporated pharmacy refill as a viable source for 
measuring treatment adherence.[16-18]  Pharmacy refill data is accessible via 
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administrative databases and tend to be objective as patients are unaware of being 
monitored (not subject to recall or social desirability bias, deception, etc.).[20, 23]  
Pharmacy refill methods have also been validated as correlated with virologic outcomes, 
although there is some variability in terms of which pharmacy based measures (e.g. 
MPR, PDC) are used and how they have been defined/implemented.[16, 17, 21]  While 
self-report and pharmacy refill have both individually been associated with virologic and 
immunologic response to treatment, correlation between the two have been 
inconsistent.  At an HIV clinic in Melbourne, Fairley, et al. reported correlation between 
self-report and pharm-refill after long-term follow up.  Both methods demonstrated 
increased mean adherence over time and predicted suppression of viral load (<400 
copies/mL) at >95% (pharmacy refill) and >97% (self-report).  In contrast, Garber, et al. 
found concordance between self-report and other adherence methods to vary widely 
with depending on type of measure used.  Interview-based self-report was less likely to 
be concordant with other adherence methods in comparison to diary or questionnaire.  
When comparing self-report measures and pharmacy refill studies, concordance was 
split.[22]  In a review of pharmacy refill measures and methods, McMahon, et al 
indicated that data supported pharmacy refill as being a better predictor of outcomes 
than self-report.  However, they also reported mixed concordance when evaluating ten 
studies between self-report and pharmacy refill.[16]  Despite the number of successful 
implementations of adherence studies using both methods, concordance varies and is 
highly dependent on measure definitions, administration method (interview, VAS, 
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MASRI for self-report), duration of follow-up, and pharmacy-based measurement types 
(e.g. MPR, PDC, etc.). 
 
2.4 Methods  
2.4.1 Design and NHS Study Population   
This is a retrospective cohort study design of data collected prospectively among 
members of the US Military HIV Natural History Study (NHS).  The NHS is a longitudinal, 
multi-site, open enrollment cohort study consisting of HIV-infected active duty and DoD 
beneficiaries 18 years and older.  Since the inception of the study in 1986, over 5800 
subjects have been enrolled.  Participants are provided free access to healthcare 
services, medications, and meet with a HIV practitioner approximately every six months 
at one of the military treatment facility (MTF) HIV sites.   Demographics, laboratory 
measures including HIV disease indicators, self-reported adherence, medication history, 
and other health information are collected at each six-month visit.  For those who retire 
or separate due to disability, participants are provided travel funds to return to the 
nearest HIV clinic site bi-annually.[24, 25]   All study participants provided informed 
written consent.  The Institution Review Board (IRB) approved the main NHS protocol at 
each medical center site.[24]  
 
2.4.2 Data Sources/Collection 
All information related to this sub-study was extracted from the NHS database.  
Data files contained information about study participants’ demographics, military 
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specific classifications (e.g. rank, duty status), laboratory data, self-reported adherence, 
medical history, two sources of medication data (self-reported and pharmacy refill), self-
reported behaviors (e.g. smoking, drinking, piercing), and site information. 
 
Adherence measures were collected from two sources.  The first source of 
adherence data was self-reported by study participants who completed the RV168 Case 
Report Form (CRF) with the assistance of an interviewer coordinator at each scheduled 
six-month site visit (see Appendix for adherence question).  Self-report data was 
available for a five-year period from 2006-2010.  The self-report adherence question on 
the CRF was based on the Medication Adherence Self-Report Inventory (MASRI) 
questionnaire with visual analogue scale (VAS) which has been validated previously by 
multiple studies.[4, 26]  With the aid of an interviewer, study participants were 
prompted to view the VAS and to indicate on the scale (0-100%) their estimated 
adherence to HIV treatment within the past month (see self-report question in 
Appendix).  Antiretroviral regimen adherence was the unit of measure (versus 
adherence by drug or by class).  Questions related to missed doses (nonadherence) 
were asked along with follow-up questions inquiring about possible reasons for 
nonadherence (e.g.  forgot to take pills, wanted to avoid side-effects, etc.).  
 
The second source, pharmacy refill data (2001-2009) was obtained by NHS from 
the Pharmacy Data Transaction Service (PDTS), a DoD centralized medication database 
which contains refill data for all prescriptions dispensed at Military Treatment Facilities 
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(MTFs), mail order, and private/commercial pharmacies that bill TRICARE.  This data 
contained the required fields (e.g. medication dispense date, days of supply, 
antiretroviral name, and antiretroviral class) upon which the pharmacy refill adherence 
measures were based.  Additional supplemental medication data outside of PDTS was 
also captured by NHS.  This data was derived from a variety of sources including doctor's 
notes and medication profiles from the electronic medical record, copies of records 
patients bring from visits to the VA or civilian facilities, and patient interviews.       
 
Laboratory data/results related to virologic and immunologic response outcomes 
were measured directly (not self-reported) at each six-month visit.  Data about the 
assays used to measure viral load was capture by site and time (visit date). 
 
Covariates potentially mediating the association between adherence and HIV 
disease indicators were obtained from the NHS database.  These included demographics 
(race, gender, marital status), military specific classifications (rank, duty status), location 
specific covariates (HIV site, proximity to HIV clinic), HIV associated factors (nadir CD4), 
behavioral risk factors (smoking, alcohol, and piercing status), and co-morbidities (Hep B 
and Hep C coinfection).  Hepatitis B and C coinfections are relevant to consider due to 
potential hepatotoxic effects of antiretroviral therapy.[27]  This may result in 
discontinuation or result in other complications impacting adherence.   
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2.4.3 Definition 
Adherence measures for pharmacy refill PDC was defined as the number of days 
supplied by medication(s) over the number of eligible days in time interval (six month 
blocks).  Six months was chosen as a reasonable time interval to measure adherence 
longitudinally.  Whereas the majority of adherence studies evaluated adherence six 
months or less, McMahon, et al. suggested that shorter durations of adherence 
assessment and use of pharmacy refill measures to predict future outcomes were less 
accurate.  In addition, as many prescriptions had large values for days supply (e.g. 90, 
120, etc.), shorter periods of adherence assessment would automatically calculate (and 
possibly overestimate) high adherence whereas six months would provide sufficient 
time to capture any potential nonadherence.  Thus, adherence time intervals were 
defined as the first six months (H1) and last six months (H2) of each calendar year (CY).  
Measurement periods for adherence would be as follows: (CY2005H1, CY2005H2, 
CY2006H1, CY2006H2, etc.) 
 
Two pharmacy refill adherence measures were proposed: Proportion of days 
covered by at least any single antiretroviral (PDCS) and proportion of days covered by a 
clinically acceptable regimen (PDCC).  While PDCS required only evidence of any single 
antiretroviral to count towards the numerator, PDCC required evidence of antiretrovirals 
that met predefined clinical criteria.  It is hypothesized that the true adherence falls 
somewhere between the less stringent PDCS (slightly overestimates true adherence) and 
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the more clinically robust adherence measure (rigidity of PDCC rules may underestimate 
true adherence).  
*Clinical criteria for PDCC (must have met at least one antiretroviral 
combination/criterion below): 
NRTI >=3  
NRTI >= 2 and NNRTI >=1 
NRTI >= 2 and PI Booster>=1 
NRTI>=2 and PI>=1 
NRTI>=1 and NNRTI>=1 and (PI>=1 or PI Booster>=1) 
NNRTI>=1 and (PI>=1 or PI Booster>=1) 
Fusion Integrator>=1 
Integrase Inhibitor >=1 
Entry Inhibitor>=1 
 
2.4.4 Pharmacy Refill Medication Adherence Database 
Capture of self-reported adherence was straight-forward.  Study participants 
pointed to the VAS to the interviewer to indicate estimated adherence levels (0-100%) 
to antiretroviral treatment in the past month.  This adherence data was inputted into 
the NHS database and eventually extracted for analysis purposes.   
 
Pharmacy refill adherence, on the other hand, required additional coding and 
manipulation of pharmacy refill data to generate the information required to calculate 
adherence (PDC).  A pharmacy refill medication adherence medication database was 
created to 1) store the historical pharmacy refill data of all participants from 2001-2009, 
2) produce daily adherence records to help calculate the proportion of days covered 
(PDC) and 3) due to the concomitant and complex nature of HIV regimens, create 
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additional fields to capture adherence metadata such as antiretroviral class and 4) 
create two daily adherence fields to support calculation of the two pharmacy refill 
adherence measures: PDC (any single ART) and PDC (clinical criteria).  The fields in the 
adherence database included date dispensed dates, HAART class, and other fields were 
used to validate treatment coverage.  
 
While the design, business rules, and implementation of the adherence database 
may be unique to this study, the conceptual framework leveraged the research 
previously described by others.  The creation of daily records is a similar approach to 
what was described by Leslie, et al.[28, 29]  Whereas Leslie, et al., created a column (i.e. 
field) for each daily record during the six-month interval (e.g. day1, day2, day3 ….  day 
180), our database reflected the daily records as rows due to the lengthy follow up 
period with up to several years’ worth of records per participant.  Each daily adherence 
record included information about the study participant (unique study/patient 
identifier), generic name and product name of the medication, dates the prescription 
was written and dispensed, and days supply of medication.  Additional fields were 
created to capture adherence information antiretroviral class type (e.g. NRTI, NNRTI, PI, 
PI booster, Fusion Integrator, Integrase Inhibitor, Entry Inhibitor).  For fixed dose 
combination medications, each component was classified.  For example, an individual 
on Atripla (Efavirenz, Emtricitabine, and Tenofovir) would get “credit” for exposure to 
NNRTI and 2 NRTIs.   
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Once the structure of the database was established, code was written in SQL to 
utilize dispense dates along with the days supply for each participant’s pharmacy refill 
history to populate existing fields.  For example, a 30-days supply of Atripla with 
dispense date of March 3, 2008 would result in the update of daily records spanning 
Mar 3, 2008 – April 2, 2008 to receive “credit” (i.e. NNRTI=1, NRTI=2, etc.) for treatment 
coverage.  Each prescription would be analyzed per participant until all daily records and 
associated adherence fields were updated.   
 
After the code applied removed daily records per exclusion rules (described in 
next section), the final phase of the code assigns adherence values for each daily 
records based on the PDCS and PDCC criteria (adherence = 0 or 1 depending on criteria).  
The total number of eligible records during the time interval (PDC score for the first six 
months of 2005, PDC for the second six months of 2005, etc.)  
 
2.4.5 Daily record adjustments and exclusions 
A number of rules were implemented to adjust for factors unrelated to 
nonadherence that would artificially lower a participant’s PDC score.  Such issues 
include early pick up of medications between refills, extended gap periods between 
refills unrelated to nonadherence, missing or incomplete data (participants seek care at 
the VA): 
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1) Shifting due to overlap: As described earlier, Leslie, et al. provided guidance on 
shifting dates to account for the scenario where medication was picked up a few 
days to a week earlier before the end of the refill period.  Without making an 
adjustment, the PDC would be underestimated as the days of overlap between refills 
would not be credited in the numerator.  To alleviate this issue, for new refills only, 
the daily records were shifted to the day after the medication of the previous refill 
was scheduled to complete.  For example if an individual’s 30-days supply of 
medication X was to complete by April 5 and the new refill was picked up a few days 
earlier on April 2, an adjustment would be made to the database records such that 
the new 30-days supply would not begin until April 6.   
 
2) Gap days exclusion: To account for large gaps of missing medication data in a 
member’s history (which are hypothesized to be unrelated to non-adherence) which 
would adversely negatively impact the PDC score, daily records were excluded from 
the PDC denominator if gaps between the end of a medication’s refill period and the 
start of the next dispensed medication exceeded 120 days.  Such reasons include, 
drug stockpiling, temporarily away or out of the country, missing records (obtaining 
medications from the VA). 
 
3) Final refill exclusion: Once the study participant completed the days supply of the 
last refill, all daily records after completion date should be excluded as not to impact 
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the PDC calculations (e.g. database removed records from both the numerator and 
denominator after completion) 
 
2.4.6 Statistical Analysis 
After development of the three adherence measures (self-report, PDCS (any single 
antiretroviral) and PDCC (standard antiretroviral regimen)), a number of analytical methods 
were performed to describe and evaluate the adherence measures individually, compare 
adherence measures to one another (self-report vs PDC), and to evaluate the measures 
against HIV disease indicators (outcomes).  The objectives of the analysis were to: 
1) establish time intervals and describe the population,  
2) calculate and compare adherence rates per measure,  
3) evaluate adherence and HIV disease indicator rates over time,  
4) describe the correlation between adherence rates and outcomes (HIV disease 
indicators), and 
5) evaluate the association between adherence rates and outcomes over time in a 
repeated measures analysis while adjusting for known covariates. 
 
2.4.7 Establishing Time Intervals and Describing the Population 
Since longitudinal data was available for a five year period, time intervals were 
established to properly characterize adherence for the entire population.  Self-report 
adherence measures were described in six-month intervals from 2006-2010.  Each six-
month interval represented the first half or second half of a calendar year (e.g. CY2006H1 – 
38 
 
Jan to Jun 2006, CY2006H2 – July 2006-Dec 2006).  If multiple visits fell within a six-month 
interval, the self-report adherence value from the last visit of the interval would serve as 
the adherence “surrogate” for that six-month period.  To better compare the results 
between self-report and pharmacy refill data, the same six-month intervals and five year 
timeline for pharmacy refill was desired.  However, as medication data was unavailable for 
2010, six-month intervals were described to the closest five year period (2005-2009) 
available for pharmacy refill measures.  Pharmacy refill measures were similarly described 
in six-month intervals representing the first half or second half of a calendar year (e.g. 
CY2005H1 – Jan to Jun 2005 and CY2005H2 – Jul to Dec 2005).  Pharmacy refill adherence 
scores (PDC) were derived by aggregating daily adherence records spanning each six-month 
interval.  In certain instances, daily records were removed from the denominator if they met 
specific exclusionary criteria as previously described. The remaining eligible daily records 
were aggregated into the numerator/denominator to calculate the PDC for each six-month 
interval. 
 
With slightly different timelines and adherence sources, the sub-populations for 
self-report and pharmacy refill were considered separately.  Descriptive analyses were 
performed to characterize the distributions of demographic and risk factors associated 
with adherence and outcomes for both sub-populations. Proportion of individuals in 
both sub-populations was assessed to describe overlap.  Univariate analysis was 
performed on demographic variables and risk factors associated to adherence or HIV 
disease indicators.  Due to the number of granular categories, some fields were 
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recategorized to broader classifications to avoid small cell sizes and/or for more 
meaningful groupings.   
 
2.4.8 Calculate and Compare Adherence Rates per Measure   
Once the descriptive analysis was complete, the adherence rate per sub-population 
was calculated at the individual and population level.  For each individual, the mean 
adherence was calculated across all available six-month intervals per individual.  The 
individual adherence rates were then used to calculate the overall adherence rate for each 
adherence measure.  Adherence rates were classified into the following categories: 
Adherent (>=90%), and non-adherent (>=0-30%, >=30-60%, >=60-90%,).  To evaluate 
concordance between self-report and pharmacy refill, a subset of individuals were 
identified who had adherence rates in both sources for the same six-month intervals.  A 2x2 
table was created to assess the level of agreement of adherence using the (>90%) adherent 
classification among this subset. The Cohen’s kappa coefficient test was performed to 
assess the inter-rater agreement between self-report and pharmacy refill in identifying the 
adherent (90%) group.  This test was performed twice: once to compare self-report against 
PDCC and self-report against PDCS.   
 
2.4.9 Evaluate Adherence and HIV Indicator Rates Over Time 
When examining adherence trends over time, follow up time points were 
established for each six-month interval in which study participants had adherence and 
outcome data.  A study participant’s initial follow up time point (follow up period =1) 
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was assigned upon evidence of the first self-reported (or pharmacy refill) adherence and 
corresponding HIV disease indicator result during the study period.  Each follow up 
period would then be assigned sequentially assuming adherence and outcome data 
were available for the corresponding six-month interval (follow up period = 2 if 
adherence data is available six months after follow up period=1).  Therefore, an 
individual could have a maximum of 10 follow up periods (10 six-month intervals for the 
entire five-year study period.  If gaps existed (e.g. an individual was gone for six months 
and returned), the follow up period would reflect the gap by skipping a follow-up 
period.  (i.e. individual has initial visit - follow up period = 1, individual has no data for 
six months, but returns the following period reports adherence at next visit – the next 
follow up period assigned will be 3).  This ensured that duration between visits was 
consistently and properly accounted for.  Cross tabulations of adherence against follow 
up time (up to ten six-month intervals) were performed to describe adherence trends 
longitudinally for each subpopulation.  Treatment adherence was categorized into the 
following groups: >=0-30%, >=30-60%, >=60-90%, and >=90%.       
 
To better evaluate the longitudinal relationship between adherence measures and 
HIV disease indicator data (viral load and CD4 counts), outcomes were also described for 
six-month intervals for each measure.  Primary endpoints captured at each six-month visit 
included viral load (copies/mL) and cd4 counts (cells/mm3).  Viral load was categorized into 
the following groups: <=50, 51 to 999, 1000 to 9999, and >=10000 copies/mL.  To detect 
immunologic response over time, cd4 was categorized as: <=200, 200 to 349, 350-499, and 
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>= 500 cells/mm3.  In instances where multiple outcomes were recorded per interval, the 
latest outcome was selected to ensure that outcomes (viral load, cd4 count) followed the 
exposure (adherence) as much as possible during each six-month interval.  Other HIV 
virologic longitudinal studies have similarly implemented rules to select a single outcome 
value to serve as the surrogate for each interval period.   
 
2.4.10 Correlation Between Adherence Rates and Outcomes (HIV Disease Indicators) 
Two analytical approaches were performed to examine the correlation between 
adherence measures and viral load.  The first approach was to perform a cross 
tabulation between categorical adherence and categorical viral load for all observations 
per measure.  The following crude associations were evaluated: Self-Report vs Viral 
Load, PDCC vs Viral Load, PDCS vs Viral Load.   
 
For the second approach, the availability of repeated measures (HIV disease 
indicators), along with the potential clustering effect of HIV clinic/site and proximity to 
HIV clinic warranted the use of a mixed effect regression model to detect an association 
between treatment adherence and HIV disease indicators while adjusting for random 
effects and other known covariates.  Unlike the crude analyses, both adherence and HIV 
disease indicators were treated as continuous variables.  Proximity to HIV clinic/site 
served as a proxy for access to HIV services/treatment.  In addition to demographic 
factors, other covariates included follow up (time), rank as a proxy for education, duty 
status, smoking, alcohol use, hepatitis B and C coinfection, nadir CD4.  Each candidate 
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variable was examined individually in the mixed effect model with viral load as the 
continuous dependent variable, follow up time as the independent variable, and site 
and the individual included as the random effects.  For model fitting, the stepwise 
method using backwards elimination approach was utilized with all candidate predictors 
included in the model.  After running the model, the least significant variable (highest p-
value) was removed and the mixed effect model was rerun.  This was repeated until 
only a parsimonious set of significant  (p < .05) covariates remained in the model.  
Backwards elimination was chosen over other approaches (e.g. forward selection and 
stepwise regression) because some covariates don’t predict well individually, but do 
appear to be relevant when their joint predictive capability is considered.  While one of 
the advantages of the mixed model is the ability to perform the analysis with missing 
values, records are dropped resulting in loss of information.  Therefore, as described in 
the next section, missing values were either imputed or given a code to indicate 
missingness.   
 
2.4.11 Addressing Missing Values 
Fields were evaluated for missing values.  Two approaches were considered.  The 
first approach was to codify missing values within the data set and to run the mixed 
effect model as is.  The second approach was to utilize missing imputation methods.  
Missing values were determined to be missing at random (MAR).  The pattern of 
missingness was not monotone.  PROC MI from SAS was implemented to create multiple 
imputations (50).  The results from the 50 imputations were pooled and coefficient and 
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p-values were obtained via PROC MIAnalyze.  To determine whether the PROC MI 
methods were valid, a subset of the data with complete records were ablated.  
Approximately 20% of records were randomly nulled to simulate “missing” records.  
PROC MI method was applied to impute the fictitious missing records.  After completing 
the imputation steps, the results derived from PROC MIAnalyze were compared to the 
results obtained running the complete table using PROC Mixed.  If the results were 
deemed comparable, the PROC MI methods would be deemed valid.  Finally, PROC MI 
method was compared to running the PROC MIXED method with missing values codified 
(e.g. missing = ‘9’).  If no difference was detected, the latter method would be used. 
 
The daily adherence database development was constructed in SQL Server using 
SQL Management Studio.  Tables were referenced and analyzed using SAS Enterprise. 
 
2.4.12 Sample Size and Power Calculations 
The following is an equation reduced from an exchangeable correlation matrix 
described and derived in detail in Liu and Liang’s 1997 Biometrics paper.[30]  This equation 
is useful for calculating sample sizes and power for correlated observations in longitudinal 
studies: 
𝑚 =
(𝑧1−∝/2 + 𝑧1−𝛽)
2
(𝜋1𝑝𝑜(1 − 𝑝𝑜) + 𝜋0𝑝1(1 − 𝑝1))(1 + (𝑛 − 1)𝜌)
𝑛𝜋0𝜋1(𝑝1 − 𝑝𝑜)2
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The table below displays the sample sizes needed to detect a difference as specified 
between p0 and p1 with p0 reflecting the prevalence of the response  (e.g. virologic failure)  
in the referent group and p1 reflecting the prevalence of the response in the comparison 
group.  Multiple scenarios for 𝜌 (0.2, 0.5, 0.8) are shown to reflect the within-group 
correlation of the repeated measure of interest for each aim.  For example, in the first row 
for Aim 1, a minimum total sample size of 480 (240 per group) is needed to detect a 
difference (p0=0.25 and p1=0.35) assuming a 5% significance, 𝜌=0.2, and achieving 80% 
power.  
 
 
Table 1 
Sample Size Calculation for Correlated Observations 
 n p0 p1   M 
Sample 
size total 
Difference Comment 
0.2 3 0.25 0.35 0.5 0.5 240.15 480 10% Aim 1, Virologic Failure 
0.5 3 0.25 0.35 0.5 0.5 343.07 686 10% Aim 1, Virologic Failure 
0.8 3 0.25 0.35 0.5 0.5 445.99 892 10% Aim 1, Virologic Failure 
 
 
 
2.5. Results 
2.5.1 Baseline Demographics and other Covariates 
Figure 1 shows the demographic distributions of the two sub-populations of 
interest: self-report (1571 individuals at baseline) and pharmacy refill (1458 individuals 
at baseline).  Baseline is defined as the first evidence of recorded adherence with a 
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corresponding outcome during the five-year study period (2006-2010 for self-report; 
2005-2009 for pharmacy refill).  The populations were predominately male, racially and 
ethnically diverse.  Average age at baseline was 33 years for pharmacy refill and 34 
years for self-report sub-populations.  Figure 2 shows the overlap between both sub-
populations with 1233 participants residing in both groups.     
The average follow up time was 2.5 years with 4 data points (adherence and 
corresponding HIV disease indicator result) for the self-reported population.  For the 
pharmacy refill population, the average follow up time was 3 years with 5 data points 
(adherence and corresponding HIV disease indicator result).   
 
The study populations consisted predominately of enlisted males serving in 
active duty at time of enrollment.  Slightly more than half of the study participants were 
single with about 30% cohabitated which included both couples that were married 
(including those whose spouse was away serving abroad) and unmarried couples living 
together.   
 
For health status, the mean nadir cd4 for both populations averaged in the low 
240 range (cells/mL) with hepatitis coinfection rates ranging 8.7%-9.0% at time of 
enrollment for Hep B and 7.4%-8.2% range for Hep C.  Of those that provided risk 
behavior information for smoking, drinking, and piercing, approximately 75% reported 
never having smoked, slightly over half consuming 2 alcoholic beverages a day, and over 
80% reported never having any piercings.   
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Variables (Self-Report) 
Total 
(n=1571) 
 Variables (Pharmacy 
Refill) 
Total 
(n=1458) 
           
Demographics (at 
baseline) 
  Demographics (at 
baseline) 
 
 Age   33 years   Age   34 years 
 Gender     Gender   
  Female  109 (6.9%)    Female  56 (3.8%) 
  Male  1462 (93.1%)    Male  1402 (96.2%) 
 Race/Ethnicity     Race/Ethnicity   
  Black  653 (41.6%)    Black  631 (43.3%) 
  Hispanic  148 (9.4%)    Hispanic  142 (9.7%) 
  Other  94 (6.0%)    Other  67 (4.6%) 
  White  676 (43.0%)    White  618 (42.4%) 
 Rank (at Baseline)     Rank (at Baseline)  
  Enlisted  1219 (77.6%)    Enlisted  1214 (83.3%) 
  Officer  159 (10.1%)    Officer  148 (10.2%) 
  Warrant  9 (0.6%)    Unknown  85 (5.8%) 
  Unknown  184 (11.7%)    Warrant  11 (0.8%) 
 Marital Status 
(Current) 
   Marital Status 
(Current) 
 
  Cohabitating  490(31.2%)    Cohabitating  435(29.8%) 
  Single  820 (52.2%)    Single  798 (54.7%) 
  Separated  201 (12.8%)    Separated  160 (11.0%) 
  Unknown  60 (3.8%)    Unknown  65 (4.5%) 
 Duty Status (at 
Baseline) 
   Duty Status (at 
Baseline) 
 
  Active Duty  1084 (69.0%)    Active Duty 1082 (74.2%) 
  Dependent  78 (5.0%)    Dependent 12 (0.8%) 
  Other  36 (2.3%)    Other  9 (0.6%) 
  Retired  268 (17.1%)    Retired  257 (17.6%) 
  Missing  105 (6.7%)    Missing  98 (6.7%) 
 Nadir_CD4  241 
(counts/mm3) 
  Nadir_CD4  243 
(counts/mm3) 
Figure 1 - Demographics 
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Figure 2 – Study Population 
 
 
           
Variables (Self-Report) 
Total 
(n=1571) 
Variables (Pharmacy Refill) 
Total 
(n=1458) 
           
Risk Factors    Risk Factors   
 Smoking (Ever Smoked)    Smoking (Ever Smoked)  
  Ever Smoked 288 
(18.3%) 
   Ever Smoked 236 
(16.2%) 
  Never Smoked 868 
(55.3%) 
   Never Smoked 702 
(48.1%) 
  Missing 415 
(26.4%) 
   Missing  520 
(35.7%) 
 Drinking (Alcohol 
Consumption) 
   Drinking (Alcohol 
Consumption) 
 
  Heavy  288 
(18.3%) 
   Heavy  237 
(16.3%) 
  Moderate 237 
(15.1%) 
   Moderate  192 
(13.2%) 
  Rarely Drank 594 
(37.8%) 
   Rarely Drank 480 
(32.9%) 
  Missing 452 
(28.8%) 
   Missing  549 
(37.7%) 
 Piercings (Ever Received 
Piercings) 
   Piercings (Ever Received 
Piercings) 
 
  Ever Pierced 209 
(13.3%) 
   Ever Pierced 160 
(11.0%) 
  Never Pierced 940(59.8%)    Never Pierced 774 
(53.1%) 
  Missing 422 
(26.9%) 
   Missing  524 
(35.9%) 
 Heb B Coinfected 136 (8.7%)   Heb B Coinfected 131 (9.0%) 
 Hep C Coinfected 123 (7.8%)   Hep C Coinfected 120 (8.2%) 
Figure 3 – Risk Factors 
 
Study Population 
Self Report  
n=1571 
Pharm Refill  
n=1458 Both 
n=1233 
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2.5.2 Adherence  
As shown in figure 4, mean adherence (Adh) over time was calculated for self-
report and pharmacy refill populations.  Self-reported adherence had the highest 
proportion of individuals (89%) reporting overall mean in the optimal >=90% group.  In 
contrast, only a third (33%) of individuals from pharmacy refill using the clinical criteria 
(PDCC) reflected Adh>=90%.  For the clinical criteria group, the largest proportion of 
individuals (50.6%) reflected marginal adherence at >=60-90%.  For single drug criteria 
(PDCS), 60.4% of individuals had mean adherence in the optimal group >=90%, nearly 
twice the rate of the clinical criteria group (33%).  Regardless of the PDC criteria used, 
neither PDC measures reflected the high proportion of optimal adherers observed in the 
self-report group. 
       Figure 4 – Adherence Category Distribution 
                                           
 
 
 
 
 
 
0% 1% 10% 
89% 
Adherence Category Distribution  
(Self-Report) 
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Adh>=30-60
Adh>=60-90
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Adherence Category Distribution 
 (PDC Single Drug Criteria) 
Adh>=0-30
Adh>=30-60
Adh>=60-90
Adh>=90
3% 
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32% 
Adherence Category Distribution  
(PDC Clinical Criteria) 
Adh>=0-30
Adh>=30-60
Adh>=60-90
Adh>=90
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Cohen’s Kappa is a statistical test to measure inter-rater agreement between 
two methods/observers in classifying subjects into groups.  Cohen’s Kappa in this 
implementation rates how well self-report (vs. pharmacy refill) is able to classify 
participants into either the optimal adherers >=90% or nonadherers <90%.   Figure 5, 
shows the results of the Cohen’s Kappa coefficient test results.   The results indicate 
only slight level of agreement between self-report and PDC in detecting optimal 
adherers (>90%).  The coefficient for self-report vs PDCC was 0.046, SE:0.0075 while self-
report vs PDCS also indicated only slight agreement at 0.055, SE: 0.011.  The third table 
shows a fictitious scenario that would have to occur in order to obtain a 0.65 index 
score.      
 
 Cohen's Kappa Agreement (Self Report vs PDCC) Cohen's Kappa Agreement (Self Report vs PDCS) 
  Self-Report    Self-Report  
  yes* No    yes* No  
PDCC yes* 2298 110 2408  yes* 3053 175 3228 
 No 2091 209 2300  no 1336 144 1480 
  4389 319 4708   4389 319 4708 
          
 *assuming adherence >= 90%   *assuming adherence >= 90%  
 Cohen's Kappa Index: 0.0461 SE:0.0075  Cohen's Kappa Index: 0.0547 SE:0.011 
          
 Hypothetical Scenario    
Kappa Agreement 
  
  Self-Report   < 0 Less than chance agreement 
  yes* no   0.01–0.20 Slight agreement  
 yes* 4300 110 4410  0.21– 0.40 Fair agreement  
PDC No 89 209 298  0.41–0.60 Moderate agreementt  
  4389 319 4708  0.61–0.80 Substantial agreement 
      0.81–0.99 Almost perfect agreement 
 *assuming adherence >= 90%       
 Cohen's Kappa Index: 0.6549 SE:0.0228      
Figure 5 – Cohen’s Kappa Agreement 
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Another method to assess adherence is to evaluate it longitudinally over time.  In 
figure 6a, adherence was plotted over time (maximum of 10 follow up period time 
points).  For self-report, a steady increase in percentage of individuals in the optimal 
adherence group (>=90%) was observed with an initial proportion of 91.4% at follow up 
period=1 to 95.2% of individuals at >=90% during follow up period=10.  In contrast, 
figure 6b and 6c pharm refill using PDC trended at a lower showed more variability per 
time point.  No obvious adherence trend could be ascertained.  The variation suggested 
some reliability, data, or methodologic issues leading to potential misclassification of 
individuals’ adherence status on a daily and aggregate basis. 
 
 
Self-Reported Adherence Over Time                   
  
 
  1 2 3 4 5 6 7 8 9 10 Total 
AdhCatg             
Adh >=0-30 Freq 14 7 8 4 9 6 0 3 5 0 56 
 (%) 0.89 0.7 0.84 0.47 1.15 0.82 0 0.58 1.54 0  
Adh >=30-60 Freq 23 9 8 7 5 10 7 6 3 0 78 
 (%) 1.46 0.9 0.84 0.82 0.64 1.36 1.03 1.17 0.92 0  
0
20
40
60
80
100
1 2 3 4 5 6 7 8 9 10
Follow Up Period (six month increments)
Adh >=0-30 Col Pct
Adh >=30-60 Col Pct
Adh >=60-90 Col Pct
Adh >=90 (%)
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Adh >=60-90 Freq 98 58 54 48 35 45 33 21 14 1 407 
 (%) 6.24 5.8 5.7 5.61 4.49 6.14 4.87 4.08 4.31 4.76  
Adh >=90 Freq 1436 926 878 796 731 672 637 485 303 20 6884 
 (%) 91.41 92.6 92.62 93.1 93.72 91.68 94.09 94.17 93.23 95.24  
Total Freq 1571 1000 948 855 780 733 677 515 325 21 7425 
 (%) 21.16 13.47 12.77 11.52 10.51 9.87 9.12 6.94 4.38 0.28 100 
Figure 6a - Self-Reported Adherence Over Time 
 
 
       Pharmacy-based Refill (PDC Single Drug Criteria) Adherence Over Time 
                   
  1 2 3 4 5 6 7 8 9 10 Total 
Adh Catg             
Adh >=0-30 Freq 10 10 6 3 2 5 2 6 2 1 47 
 (%) 0.69 0.87 0.58 0.32 0.24 0.69 0.29 0.95 0.33 0.2  
Adh >=30-60 Freq 92 70 61 59 60 54 55 53 33 16 553 
 (%) 6.31 6.09 5.87 6.23 7.18 7.45 7.99 8.43 5.38 3.18  
Adh >=60-90 Freq 327 318 266 259 218 206 177 167 157 84 2179 
 (%) 22.43 27.68 25.6 27.35 26.08 28.41 25.73 26.55 25.61 16.7  
Adh >=90 Freq 1029 751 706 626 556 460 454 403 421 402 5808 
 (%) 70.58 65.36 67.95 66.1 66.51 63.45 65.99 64.07 68.68 79.92  
Total Freq 1458 1149 1039 947 836 725 688 629 613 503 8587 
 (%) 16.98 13.38 12.1 11.03 9.74 8.44 8.01 7.33 7.14 5.86 100 
Figure 6b - Pharmacy-based Refill (PDC Single Drug Criteria) Adherence Over Time 
 
 
 
 
0
20
40
60
80
100
1 2 3 4 5 6 7 8 9 10
Follow Up Period (six month increments)
Adh >=0-30 (%)
Adh >=30-60 (%)
Adh >=60-90 (%)
Adh >=90 (%)
52 
 
         Pharmacy-based Refill (PDC Clinical Criteria) Adherence Over Time 
                    
  1 2 3 4 5 6 7 8 9 10 Total 
Adh Catg             
Adh >=0-30 Freq 103 58 49 56 52 45 39 39 29 27 497 
 (%) 7.06 5.05 4.72 5.91 6.22 6.21 5.67 6.2 4.73 5.37  
Adh >=30-60 Freq 275 209 199 162 127 106 94 85 68 55 1380 
 (%) 18.86 18.19 19.15 17.11 15.19 14.62 13.66 13.51 11.09 10.93  
Adh >=60-90 Freq 369 370 323 307 255 245 229 214 195 122 2629 
 (%) 25.31 32.2 31.09 32.42 30.5 33.79 33.28 34.02 31.81 24.25  
Adh >=90 Freq 711 512 468 422 402 329 326 291 321 299 4081 
 (%) 48.77 44.56 45.04 44.56 48.09 45.38 47.38 46.26 52.37 59.44  
Total Freq 1458 1149 1039 947 836 725 688 629 613 503 8587 
 (%) 16.98 13.38 12.1 11.03 9.74 8.44 8.01 7.33 7.14 5.86 100 
Figure 6c - Pharmacy-based Refill (PDC Clinical Criteria) Adherence Over Time 
 
 
 
To assess correlation between the primary exposure variable and the outcome, 
bivariate analysis was performed.  A crosstab of viral load (categorical) against 
adherence (categorical) was performed for each of the three adherence measures.  For 
self-report, a dose-response like association was seen for viral suppression (<=50 copies) 
with adherence increasing steadily from >=0-30 (25%), >=30-60 (39.74%), >=60-
90(56.8%), and finally >=90(84.82%).   A similar type of response was observed, but in 
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the opposite direction for viral load >=10000 copies: Adherence decreased steadily >=0-
30=(42.86), >=30-60(25.64%), >=60-90(14.5%), and >=90(2%).  For both PDC clinical and 
PDC single drug, a dose response relationship was not seen between viral load and 
adherence.  Instead the adherence percentages along the viral suppression (<=50 
copies) row were relatively flat.      
 
 
SELF-REPORTED ADH vs VIRAL LOAD     
  Adhere_cat  Total 
Vb_copies_cat  >=0-30 >=30-60 >=60-90 >=90  
<=50 copies Freq 14 31 231 5839 6115 
 Row Pct 0.23 0.51 3.78 95.49  
 Col Pct 25 39.74 56.76 84.82  
51 to 999 copies Freq 7 21 67 724 819 
 Row Pct 0.85 2.56 8.18 88.4  
 Col Pct 12.5 26.92 16.46 10.52  
1000 to 9999 copies Freq 11 6 50 183 250 
 Row Pct 4.4 2.4 20 73.2  
 Col Pct 19.64 7.69 12.29 2.66  
>=10000 copies Freq 24 20 59 138 241 
 Row Pct 9.96 8.3 24.48 57.26  
 Col Pct 42.86 25.64 14.5 2  
Total Freq 56 78 407 6884 7425 
 
 
 
PDC Clinical Criteria vs VIRAL LOAD 
     
  Adhere_cat(Adhere_cat)  Total 
  >=0-30 >=30-60 >=60-90 >=90  
Vb_copies_cat      
<=50 copies Freq 311 1016 2066 3106 6499 
 Row Pct 4.79 15.63 31.79 47.79  
 Col Pct 62.58 73.62 78.59 76.11  
51 to 999 copies Freq 81 197 327 497 1102 
 Row Pct 7.35 17.88 29.67 45.1  
 Col Pct 16.3 14.28 12.44 12.18  
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1000 to 9999 copies Freq 50 70 99 171 390 
 Row Pct 12.82 17.95 25.38 43.85  
 Col Pct 10.06 5.07 3.77 4.19  
>=10000 copies Freq 55 97 137 307 596 
 Row Pct 9.23 16.28 22.99 51.51  
 Col Pct 11.07 7.03 5.21 7.52  
Total Freq 497 1380 2629 4081 8587 
       
       
       
PDC Single Drug Criteria vs VIRAL LOAD     
  Adhere_cat(Adhere_cat)  Total 
  >=0-30 >=30-60 >=60-90 >=90  
vb_copies_cat(vb_copies_cat)      
<=50 copies Freq 35 368 1682 4414 6499 
 Row Pct 0.54 5.66 25.88 67.92  
 Col Pct 74.47 66.55 77.19 76  
51 to 999 copies Freq 6 88 291 717 1102 
 Row Pct 0.54 7.99 26.41 65.06  
 Col Pct 12.77 15.91 13.35 12.35  
1000 to 9999 copies Freq 2 38 87 263 390 
 Row Pct 0.51 9.74 22.31 67.44  
 Col Pct 4.26 6.87 3.99 4.53  
>=10000 copies Freq 4 59 119 414 596 
 Row Pct 0.67 9.9 19.97 69.46  
 Col Pct 8.51 10.67 5.46 7.13  
Total Freq 47 553 2179 5808 8587 
Figure 7 – Correlation between Adherence and Viral Load observations 
 
 
 
2.5.3 HIV Disease Indicators Over Time 
While not part of the correlation activities, viral load (copies/mL) was also 
plotted over time (maximum of 10 follow up period time points) for trending purposes.  
In Figure 8a, a steady increase was observed in the proportion of virally suppressed 
individuals (< 50 copies/mL category) in the self-reported subpopulation.  In figure 8b, 
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for the pharm refill subpopulation, a lower initial baseline a smaller proportion of virally 
suppressed were observed at baseline (54%).  However, there was a dramatic increase 
of over 20% at the subsequent follow up period=2.  The percentage of individuals with 
undetectable viral load held for the remaining periods.  So while there was in general a 
lower proportion of the subpopulation within the optimal “undetectable” viral load < 50 
copies/mL, the trend over time was positive for both self-report and pharm admin.  CD4 
count was also plotted over time, but is not shown in the figures below. 
 
 
Viral Load Over Time (Self-Reported subpopulation) 
                      
  1 2 3 4 5 6 7 8 9 10 Total 
Viral Load              
<=50 Freq 1139 835 782 746 668 633 564 443 285 20 6115 
 Col Pct 72.5 83.5 82.49 87.25 85.64 86.36 83.31 86.02 87.69 95.24  
51 to 999 Freq 237 97 89 77 76 70 90 53 29 1 819 
 Col Pct 15.09 9.7 9.39 9.01 9.74 9.55 13.29 10.29 8.92 4.76  
1000to9999  Freq 99 23 52 17 15 14 13 10 7 0 250 
 Col Pct 6.3 2.3 5.49 1.99 1.92 1.91 1.92 1.94 2.15 0  
>=10000 Freq 96 45 25 15 21 16 10 9 4 0 241 
 Col Pct 6.11 4.5 2.64 1.75 2.69 2.18 1.48 1.75 1.23 0  
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Figure 8a - Viral Load Over Time (Self-Reported subpopulation) 
 
 
 
    Viral Load Over Time (Pharmacy-based Refill subpopulation) 
                      
 
  1 2 3 4 5 6 7 8 9 10 Total 
Viral Load             
<=50  Freq 788 864 833 742 660 587 562 515 519 429 6499 
 Col Pct 54.05 75.2 80.17 78.35 78.95 80.97 81.69 81.88 84.67 85.29  
51 to 999 Freq 309 157 105 107 99 68 69 67 66 55 1102 
 Col Pct 21.19 13.66 10.11 11.3 11.84 9.38 10.03 10.65 10.77 10.93  
1000to9999 Freq 122 54 42 45 27 30 25 23 12 10 390 
 Col Pct 8.37 4.7 4.04 4.75 3.23 4.14 3.63 3.66 1.96 1.99  
>=10000 Freq 239 74 59 53 50 40 32 24 16 9 596 
 Col Pct 16.39 6.44 5.68 5.6 5.98 5.52 4.65 3.82 2.61 1.79  
Total Freq 1458 1149 1039 947 836 725 688 629 613 503 8587 
 Percent 16.98 13.38 12.1 11.03 9.74 8.44 8.01 7.33 7.14 5.86 100 
Figure 8b - Viral Load Over Time (Pharmacy-based Refill subpopulation) 
 
 
 
 
Total Freq 1571 1000 948 855 780 733 677 515 325 21 7425 
 Percent 21.16 13.47 12.77 11.52 10.51 9.87 9.12 6.94 4.38 0.28 100 
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2.5.4 Modeling Results 
In Figures 9 (viral load) and 10 (cd4 counts), the significant variables remaining in 
the final models are displayed.  In self-report, for every percentage increase in self-
reported adherence, after adjusting for other relevant variables, a decrease in the 
expected log10viral load (-0.14, p<.0001) value was found.  A positive trend was 
detected for immune function over time after adjusting for covariates.  For every 
percentage increase in self-reported adherence, an increase in the expected cd4 count 
(0.88, p<.0001) value was observed.  In contrast for pharmacy refill population, both the 
clinical and single drug PDC displayed positive trends for viral load.  For every percentile 
increase in PDC, while keeping other covariates constant, a slight increase in the 
expected log10viral load (.0004, p=.19) value was observed.  The opposite trend was 
also detected for immune function with every percent increase in PDC, a decrease in cd4 
count (-.22, p=.0052) observed.  For the self-reported population, notable increases in 
log10 viral load were observed even after adjustment for Blacks (compared to Whites), 
enlisted (compared to officers), and those hep C coinfected (pre-existing condition – 
coinfection must have occurred prior to baseline).  
 
 
Figure 9 – Proc Mixed (Viral Load) 
 
Self Report - VIRAL LOAD    
Effect Values Estimate   Standard Error Pr > |t| 
Intercept  3.46 0.08 <.0001 
Self-Reported Adh  -0.014 0.0006 <.0001 
Followup Period  -0.03 0.0003 <.0001 
Rank Enlisted 0.09 0.04 0.0254 
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 Unknown 0.04 0.05 0.4874 
 Warrant -0.04 0.16 0.7874 
 Officer 0.00 . . 
Race_Ethnicity Black 0.09 0.03 0.0009 
 Hispanic -0.01 0.04 0.8097 
 Other 0.0002 0.05 0.9968 
 White 0.00 . . 
Nadir CD4 per 50 cells  -0.04 0.0004 <.0001 
Hep C Coinfection  0.12 0.04 0.0052 
Proximity to clinic Far -0.03 0.03 0.3426 
 Moderate 0.05 0.03 0.0624 
 Near 0.00 . . 
 
 
Pharmacy Refill (PDC clinical) - VIRAL LOAD   
Effect Values Estimate   Standard Error Pr > |t| 
Intercept  2.28 0.07 <.0001 
PDC  0.0004 0.0003 0.193 
Followup Period  -0.05 0.003 <.0001 
Rank Enlisted 0.15 0.05 0.0043 
 Unknown 0.06 0.08 0.4901 
 Warrant -0.07 0.19 0.7188 
 Officer 0.00 . . 
Marital Status Unknown 0.23 0.08 0.0061 
 Separated -0.05 0.06 0.3503 
 Single 0.09 0.04 0.0141 
 Cohabitating 0.00 . . 
Race_Ethnicity Black 0.13 0.04 0.0002 
 Hispanic 0.08 0.06 0.1554 
 Other 0.01 0.08 0.8997 
 White 0.00 . . 
Nadir CD4 per 50 cells  -0.06 0.06 <.0001 
Hep C Coinfection  0.14 0.06 0.0179 
Proximity to clinic Far 0.00 0.04 0.9783 
 Moderate 0.08 0.04 0.0357 
 Near 0.00 . . 
 
 
Pharmacy Refill (PDC Single Drug Criteria) - Viral Load  
Effect Values Estimate   Standard Error Pr > |t| 
Intercept  2.23 0.08 <.0001 
PDC  0.0009 0.0005 0.0981 
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Followup Period  -0.05 0.003 <.0001 
Rank Enlisted 0.15 0.05 0.0044 
 Unknown 0.06 0.08 0.4872 
 Warrant -0.07 0.19 0.7078 
 Officer 0.00 . . 
Marital Status Unknown 0.23 0.08 0.0061 
 Separated -0.05 0.06 0.3557 
 Single 0.09 0.04 0.0142 
 Cohabitating 0.00 . . 
Race_Ethnicity Black 0.13 0.04 0.0002 
 Hispanic 0.08 0.06 0.1515 
 Other 0.01 0.08 0.8971 
 White 0.00 . . 
Nadir CD4 per 50 cells  -0.06 0.006 <.0001 
Hep C Coinfection  0.13 0.06 0.0198 
Proximity to clinic Far 0.002 0.04 0.9633 
 Moderate 0.08 0.04 0.035 
 Near 0.00 . . 
 
 
Figure 10 – Proc Mixed (CD4 count) 
 
Self Report - CD4     
Effect Values Estimate   Standard Error Pr > |t| 
Intercept  196.24 20.73 <.0001 
Self-reported Adh  0.88 0.19 <.0001 
Followup Period  12.03 0.72 <.0001 
Nadir CD4 per 50 cells  52.93 1.84 <.0001 
 
Pharmacy Refill (PDC Clinical Criteria) - CD4 counts 
Effect Values Estimate   Standard Error Pr > |t| 
Intercept  272.90 20.49 <.0001 
PDC  -0.22 0.08 0.0052 
Followup Period  12.08 0.62 <.0001 
Rank Enlisted -50.71 17.50 0.0038 
 Unknown -0.86 27.32 0.975 
 Warrant -20.41 62.71 0.7448 
 Officer 0.00 . . 
Nadir CD4 per 50 cells  60.66 1.93 <.0001 
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Pharmacy Refill (PDC Single Drug Criteria) - CD4 counts  
Effect Values Estimate   Standard Error Pr > |t| 
Intercept  285.15 22.35 <.0001 
PDC  -0.31 0.12 0.0081 
Followup Period  11.96 0.62 <.0001 
Rank Enlisted -50.59 17.52 0.0039 
 Unknown -1.01 27.35 0.9705 
 Warrant -19.41 62.80 0.7573 
 Officer 0.00 . . 
Nadir CD4 per 50 cells  60.53 1.93 <.0001 
 
 
 
2.6 Discussion 
Self-reported adherence was determined to be a better measure for treatment 
adherence especially when analyzed in conjunction with viral load and cd4 and adjusting 
for known covariates.  Both the aggregate and individual level HIV disease indicator 
results were consistent with self-reported adherence trajectories over time.  Differential 
loss to follow up may have occurred as indicated by the rising tails towards the later 
follow-up periods.   Modeling results supported the crude findings that for each unit 
increase in self-reported adherence, a decrease in log10viral load was observed over 
time after adjusting for known covariates.  Liu, et al., also using a mixed effect model, 
reported after increasing percent adherence by 10%, viral load decreases of 0.18, 0.3, 
0.42, and 0.54 log units for 12, 24, 36, and 48 weeks respectively.[31]  In our study, we 
had a smaller, but comparable effect observing a decrease of 0.14 log units in viral load 
for every 10% increase in adherence.  Similarly, as expected, an increasing trend for cd4 
count was observed over time after adjustment of known covariates.   
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For the pharmacy refill measures, PDC was shown not to be as reliable a 
measure in calculating mean adherence nor adherence trends over time in this study.  
This contrasts with many other studies that have demonstrated a correlation between 
pharmacy refill based adherence and HIV indicators.  Three possible reasons are 
hypothesized as potential explanations for the poor correlation: 
1) Missing Information.  Independent of any methodology issues, cases have 
been identified in the data that have gaps of unexplained periods of time and 
yet virologic data for the corresponding period shows a consistent set of test 
results with viral suppression outcomes.  For some individuals missing 
information may be due to visiting or receiving health care services at 
another facility (VA) where NHS staff have no visibility or access to the 
medication data records.  This was confirmed in a separate subanalysis 
where records were identified meeting the following criteria: PDC < 60% with 
corresponding viral load < 200 copies/mL.  This was matched against the NHS 
medication table which consisted of medication records from a variety of 
sources including the electronic medical record, documentation brought in 
from other sources, and the patients themselves.  The dates where gaps 
occurred in the pharm refill data were cross checked against those 
supplemental medication files.  If a regimen was identified within those 
tables, the record would be flagged suggesting that the participant did in fact 
had medication, but we were unable to identify it in our pharmacy refill data.  
Approximately 138 individuals or 8.8% were found to meet this criteria.  This 
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suggests that missing data may be one area where improvements can be 
made in the future as we refine our pulls from the pharmacy data sources.   
Another reason could be due to drug stockpiling.  As HIV patients are on 
therapy longer, they may have access to more non-standard sources for 
medication, leftover pills, samples, etc. and hence delay their scheduled refill 
pickup.  A recent VA adherence study reported excluding 20% of their study 
population whom they identified as stockpilers.[32]  This was not performed 
in this study, but certainly may have benefited by performing additional 
exclusions besides the ones proposed/identified.         
 
2) Methodology Issues: A potential limitation of the methodology is the 
selection of only a single viral load during the six month time frame and not 
being as intentional about calculating the PDC period leading up to the viral 
load (7, 14, 21, 30, 60, 90 days look back).  The current method selects the 
latest viral load during the six month period and associates it to the six-
month PDC.  Related to this is how PDC is calculated.  Generally speaking, 
PDC takes into account the last refill during the period and excludes days 
after the days supply of the last refill runs out.  This alters the denominator 
and provides an adjusted PDC rate according to the last refill.  However for 
longer longitudinal studies like this one, the current process eliminates the 
days after the last final refill not until the very last prescription is found 
which could be many years later.  This means that in between every six 
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months, the study participant does not receive any “days off” at the end of 
the refill period.  The assumption is that every day counts during the entire 
six month time period unless days are appropriately excluded.  A 
modification to the current rules therefore could enforce each six month 
period to allow for exclusions based on the last refill of that time period and 
thus not overly penalize an individual that has been with the program for 
multiple six month periods. 
 
3)   Use of a conservative adherence measure: while PDC is the preferred 
measure of adherence[28], the medication possession ratio (MPR) is still 
viable and has been widely utilized for many years in adherence studies.  
While there are adjustments that can be made to refine the MPR calculation, 
most MPR implementations overestimate or inflate true adherence due to 
the reliance on days supply.  A change in medication or the pickup of a 
medication early during the measurement period could result in inflating the 
MPR beyond 100%.  So in general, PDC when done correctly tends to report 
lower, but more accurate percentages than MPR.  A lower PDC adherence 
score could cause issues when comparing to self-reported adherence scores 
that tends to already be slightly overestimated.   
 
It is essential to develop reliable, adherence measures that can be optimized by 
disease managers and clinicians to proactively follow up with HIV “poor treatment 
64 
 
adherers” even before scheduled bi-annual HIV visits.  The results of this study show 
that self-reported adherence measure is a reliable, valid, and preferred means of 
representing treatment adherence in this population.  The trends and associations 
observed between self-reported adherence and HIV disease indicators in this study are 
consistent with current research findings.  Further work is needed to refine the PDC 
measure, identify gaps, as well as validate and understand reasons for observed 
differences in adherence for race, proximity to HIV clinic, and other significant factors.  
The rules that have been implemented in the current version of the pharmacy 
adherence database can be altered to make adjustments, exclusions, and other 
modifications to ensure that the resultant PDC reflects adherence that better 
approximates current rates. 
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3 MEDIATING EFFECTS OF RACE AND DEPRESSIVE SYMPTOMS ON ADHERENCE 
AND HIV DISEASE INDICATORS 
 
3.1 Overview 
Based on the results of the last aim, in a comparison of multiple adherence 
methods, self-reported adherence was determined to be moderately correlated with 
HIV disease indicators after adjustment of covariates in repeated-measures mixed effect 
model.  The primary purpose of this aim was to leverage the selected self-report 
adherence measure in examining whether race/ethnicity and/or depressive symptoms 
played a role in mediating the relationship between medication adherence and HIV 
disease indicators.  Specific objectives of this aim are to 1) describe the impact of race 
and depressive symptoms on adherence and HIV disease indicators 2) assess the 
relationship between race/ethnicity and depressive symptoms, and to 3) evaluate the 
mediating effects of race and depressive symptoms on self-reported adherence and HIV 
disease indicators after adjustment of known risk factors.  A secondary goal was to 
assess whether reasons for missed doses varied by race/ethnicity.   
 
3.2 Background 
3.2.1 Association of Race on Virologic Response and Adherence 
Virologic response differences to HAART have been noted across different 
population subgroups despite the overall benefit and performance of HIV treatment to 
the general population.   For example, virologic response differences after HAART 
initiation have been observed among racial groups in multiple studies.  Despite similar 
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durations of HIV infection and access to healthcare, Weintrob et al discovered in the HIV 
NHS cohort that African Americans (AA) were less likely to achieve viral suppression 
compared to European Americans (EU).[1]  However, the authors acknowledged that 
their observed association may have been mediated by multiple factors including 
differences in treatment adherence.  Thus, to refine the association between race and 
virologic response after HAART initiation, treatment adherence was identified as an 
important variable for consideration for future analysis.  Shacham, et al conducted 
behavioral assessments to explore social factors associated with viral suppression.  They 
found that African American women experienced more difficulty adhering to 
medications (35% African Americans reported < 95% medication adherence compared 
to 15% Caucasians).[2]  However, African American women in this study also reported 
low income and higher rates of major depressive disorder, both factors associated with 
adherence.  Oh, et al controlled for confounders such as age, financial difficulty and 
drug use, and found that whites were still considered the least nonadherent compared 
to Hispanics and blacks.[3] However, some researchers have identified other factors 
such as numeracy skills as a reason for the perceived racial differences in HIV 
medication management.[4]  This aim will evaluate whether race is a mediator between 
treatment adherence and virologic outcomes in the NHS population. 
 
3.2.2 Association of Depressive Symptoms on Adherence 
Comorbidities experienced by HIV patients that impact effective treatment 
adherence include psychosocial factors and mental health conditions.  In regards to 
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mental health diagnoses, depression has been reported as the most common mental 
health diagnosis in HIV populations.[5]  While many studies have theorized and provided 
evidence that depression is antecedent to poor adherence, the relationship may actually 
be bidirectional; depression may cause poor or nonadherence, but likewise, poor 
adherence along with other factors may increase the risk for depression.  Poor 
adherence is particularly pronounced among those who are both depressed and 
engaged in active substance abuse.[6-8]  Wagner et al, sought to confirm the impact of 
depression severity on adherence (continuous) over time, but focused more on the 
impact of specific type (cognitive vs. vegetative) and severity of depression symptoms 
on adherence over time.   They identified that patients exhibiting severe depression 
symptoms was associated with poor adherence compared to patients without 
depression.  However, they did not observe this association when comparing mild and 
moderate symptoms to non-depressed patients.[9]  Interventions to depression 
including have shown mixed findings when assessing its impact on adherence.  
Interventions can include both antidepressant medication and behavioral modification 
therapy.[10-12]  Horberg et al examined the mediating role of selective serotonin 
reuptake inhibitor (SSRI) use in assessing the relationship between depression and 
HAART adherence and virologic outcomes.  They determined that SSRI use among 
depression cases showed similar adherence rates to participants without 
depression.[10]  This suggests that adherence to depression treatment may indirectly 
improve adherence to HAART and potentially improve virologic outcomes. 
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 In regards to both race/ethnicity and depressive symptoms, Kong et al, found in 
a cohort of 7034 HIV infected patients black patients as having nearly 30% decreased 
odds of being adherent to ART compared to non-black patients.  This association 
persisted whether or not the patient had depression.  Conversely patients with 
depression on antidepressant treatment were shown to have nearly double (OR=1.92, 
95 % CI: 1.12–3.29) the odds of optimal adherence.  Wagner confirmed that while 
patients diagnosed with minor to moderate depression may need to receive treatment 
for mental health, often these patients are still able to maintain ART adherence even 
while on antidepressant treatment.  
 
3.3 Methods 
3.3.1 Data Sources/Collection 
The majority of information including study participants’ demographics 
(including race/ethnicity), military specific classifications (e.g. rank, duty status), 
laboratory data, self-reported adherence, self-reported behaviors (e.g. smoking, 
drinking, piercing), and site information. and reasons for missed doses (nonadherence 
factors) were obtained from the NHS database.  Data was collected and updated at 
scheduled bi-annual visits.  For the missed doses question, participants are asked 
“People skip or miss taking their HIV medications for various reasons. Here is a list of 
possible reasons why you may miss taking your medications. How often have you 
missed taking your HIV medications because you…(check all that apply)”.  A list of 14 
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reasons/factors were provided.  Four ordinal responses were provided: “Never”, 
“Rarely”, “Sometimes”, “Often”.     
 
In one of the sections of the NHS Case Report Form (CRF), responses about self-
reported depressive symptoms were collected annually.  Study participants were 
administered the Center for Epidemiologic Studies – Depression (CES-D) survey 
instrument (20 items).  The CES-D is a well validated and referenced survey instrument 
for detecting depressive symptoms from multiple situations and various groups.  While 
tables did exist for medical history and hospitalizations, insufficient depression data was 
extracted to confidently assess and exclude prior depression or to use to supplement or 
validate the depression information derived from CES-D.  The data sources and 
collection process of the other variables related to this analysis were described 
previously in the first aim.  
 
3.3.2 Definition 
Center for Epidemiological Studies-Depression (CES-D) is a 20-item measure 
(originally published by Radloff) asking individuals to provide feedback on how often 
over the past week they experience symptoms (e.g. feeling lonely, etc.)  For each item, 
participants were provided 4 response options: “Rarely or never (less than once a day)”, 
“Some or little of the time (1-2 days)”, “Occasionally or a moderate amount of time (2-4 
days)”, and Most or all of the time (6-7 days).  CES-D has been well validated with high 
internal consistency (Lewinsohn et al,) and used in a wide range of environments and 
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populations.[13] Higher scores indicate greater depressive symptoms.  CES-D provides 
recommended cutoffs: 
Minor or no depressive symptoms: CES-D >= 16   
Major depressive symptoms (at risk for clinical depression): CES-D < 16  
 
3.3.3 Statistical Analysis 
This purpose of this analysis was to explore the possibility of race/ethnicity 
differences in the NHS study population as it related to self-reported adherence, HIV 
outcomes, and self-reported reasons for missing medications (factors for non-adherence).   
Another goal of the analysis was to quantify and classify severity of depression symptoms 
within NHS and determine whether differences were also observed by race, self-reported 
adherence, and HIV outcomes.     
 
Much of the data and information obtained from the previous aim was leveraged to 
assist in further describing and evaluating the potential mediating effects of race and/or 
depressive symptoms on adherence and HIV disease indicators.  For example, demographic 
data related to race/ethnicity was categorized into the same groups as defined in the 
previous aim.  The degree of severity of depressive symptoms was ascertained by totaling 
all the scores from the 20 CES-D questions and classifying severity based on the standard 
cutoff (i.e. Score >=16 indicates significant depressive symptoms).  For nonadherence, a 
question listing 14 possible reasons for missed doses was asked of study participants as part 
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of the bi-annual visit (see appendix for missed doses reason questions).  After successful 
capture and reorganizing of key independent variables of interest, multiple analytical steps 
were implemented with the goal of: 
1) Describing the population by race and by depressive symptoms,  
2) Examining adherence rates over time by race and by depressive symptoms, 
3) Examining HIV outcome rates over time by race and by depressive symptoms,  
4) Assessing the relationship between race and depressive symptoms, 
5) Evaluating the association between adherence rates and outcomes over time 
using a repeated measures analysis while adjusting for race, depressive symptoms, 
and other known covariates. 
6) Describing self-reported reasons for missed doses (non-adherence) by race 
 
3.3.4 Describing the Population 
In the previous aim, self-report was shown to better reflect the association 
between adherence and HIV disease indicators.  Therefore, for the purposes of this 
analysis, the self-report subpopulation was chosen as the source population.  Within 
self-report, individuals were included in this analysis if data was available for at least 
one reported visit with CES-D responses or one reported visit with reasons for missing 
medications.  Data responses were available for the same time period (2006-2010) as 
was collected for self-reported adherence in the previous aim.  Descriptive analyses 
were performed to examine the self-report population by race and depressive 
symptoms categories.  Study participants were classified as either Black/African 
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American, White/European American, Hispanic, or Other.  Study participants were 
classified (using the CES-D cutoff of 16) at baseline as either “Major Depressive 
Symptoms” or “Mild Depressive Symptoms”. Univariate analysis was performed on 
demographic variables and risk factors associated to adherence or HIV disease 
indicators.  Other demographic fields were recategorized to broader classifications or 
meaningful groupings as previously described.   
 
3.3.5 Adherence by Race and by Depressive Symptoms 
Adherence rate was calculated at the individual and by race/ethnicity group level.  
As implemented in the previous aim, mean adherence was calculated across all available 
six-month intervals per individual.  Individual adherence rates were then aggregated to 
calculate the overall adherence rate by race/ethnicity.  Adherence rates were classified into 
the following categories: Adherent (>=90%), and non-adherent (>=0-30%, >=30-60%, >=60-
90%,).  While deciles were preferred, due to small sample size issues, non-adherent 
categories were grouped into the three categories as defined.  Depressive Symptoms 
categories were calculated by summing up the total item scores (20 items total in CES-D 
survey) per each visit where survey was completed.  For those survey responses, where 
scores were missing for individual items, the default lowest value (1 – rarely or none of the 
time) was imputed with the exception of items relating to positive feelings (e.g. As_Good, 
Hopeful, Happy, Enjoyed) which in those cases the default would be the highest value (4 – 
most or all of the time).  Without this step, there would have been individuals classified as 
not being depressed when in reality they had a score of <=16 due to incomplete data.  
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Overall mean depressive symptom score was calculated based on all available CES-D scores 
from past visits during the entire study period.        
 
3.3.6 Examining Adherence Rates Over Time by Race and by Depressive Symptoms 
When examining adherence trends over time, the same methodology 
implemented in the previous aim was used to define follow up time points for each six-
month interval in which study participants had adherence and corresponding HIV 
disease indicator data.  Six month calendar intervals (e.g. CY2006H1, CY2006H2) were 
defined as the first six months and second six months respectively of each calendar year 
for the entire study period.  Self-reported adherence HIV outcome data was fitted into 
this structure with a single adherence time point and single outcome point reflected for 
each six-month interval.     
 
Cross tabulations of adherence against follow up time (up to ten six-month 
intervals) were performed to describe adherence trends longitudinally for each 
race/ethnicity group.  Treatment adherence was categorized into the following groups: 
>=0-30%, >=30-60%, >=60-90%, and >=90%.  Cross tabulations of adherence against 
follow up time were rerun again by depressive symptom categories.  
 
To better evaluate the mediating effect of race and depressive symptoms on the 
longitudinal relationship between adherence measures and HIV disease indicator data (viral 
load and CD4 counts), cross tabulations of categorical adherence and HIV disease indicators 
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by race and another set of cross tabs by depressive symptoms category were performed.  
HIV outcomes were again described categorically using the groupings defined previously for 
six-month intervals for each measure.  Viral load was categorized into the following groups: 
<=50, 51 to 999, 1000 to 9999, and >=10000 copies/mL.  To detect immunologic response 
over time, cd4 was categorized as: <=200, 200 to 349, 350-499, and >= 500 cells/mm3.  In 
instances where multiple outcomes were recorded per interval, the latest outcome was 
selected to ensure that outcomes (viral load, cd4 count) followed the exposure (adherence) 
as much as possible during each six-month interval.  
 
3.3.7 Assessing Relationship Between Race and Depressive Symptoms 
In addition to examining the individual associations of race and depressive 
symptoms with adherence and HIV outcomes, the relationship between race and 
depression required further exploration as studies have reported mixed findings 
regarding the relationship between the two.  According to an analysis performed by the 
CDC on BRFSS data from 2006-2008, a significant difference was reported among blacks 
and whites in terms of prevalence of depression, with non-Hispanic blacks having a 
reported higher rate of depression (4%) than non-Hispanic whites (3.1%).  To explore 
this further within the NHS population, a contingency table analysis was performed to 
assess the association between race/ethnicity and depressive symptoms.  Race and 
depressive symptoms were both treated categorically in this contingency table analysis.   
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3.3.8 Evaluating Association Between Adherence and HIV Disease Indicators While 
Adjusting for Race and Depressive Symptoms in Repeated Measures Analysis 
 
Although race remained unchanged per individual throughout the study, CES-D 
scores varied over time and were available as repeated measures.  As in the first aim, 
the availability of repeated measures and the existence of both fixed effect covariates 
and random effect covariates warranted the use of a mixed effect regression modeling 
approach to evaluate the primary association between self-reported adherence and HIV 
indicators.  The primary outcomes (HIV disease indicators – viral load and cd4) were 
treated as continuous variables in the model.  Similarly the primary exposure, self-
reported adherence was also incorporated in the modeling process as a continuous 
variable.   
 
While race/ethnicity was treated categorically, depressive symptoms (CES-D) 
scores could have been treated continuously or categorically.  Since most studies classify 
severity of depressive symptoms categorically using the >=16 CES-D cutoff, it was 
decided to leave depressive symptoms as a categorical variable in the final model.  To 
account for possible effect modification by race and depressive symptoms, an 
interaction term (multiplicative) was included as race/ethnicity * categorization of 
depressive symptoms (i.e. categorized as < 16, >=16).   
 
For model fitting, the stepwise method using backwards elimination approach 
was utilized with all candidate predictors included in the model.  After running the 
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model, the least significant variable (highest p-value) was removed and the mixed effect 
model was rerun with the exception of race and ces-d score as these were the other 
primary variables of interest.  This was repeated until only a parsimonious set of 
significant  (p < .05) covariates remained in the model.  
 
3.3.9 Reasons for Missed Doses (Nonadherence Factors) by Race 
The final analysis step involved taking qualitative self-reported reasons for 
missed doses and describing it quantitatively to determine whether these 
nonadherence factors varied by race/ethnicity.  After extracting the subset of records 
associated with the self-reported population for the period 2006-2010, the responses to 
the reasons for missing doses were stratified by race/ethnicity.  Each response was 
limited to an ordinal set of values: Never, Rarely, Sometimes, Often.  The frequency 
distribution of each reason’s set of values was stratified by race (AA vs EA).  To 
determine whether an association existed between race/ethnicity and reasons for 
missed doses, the chi square statistic (test for independence) was performed for each 
factor.      
 
To better summarize and quantify the impact of missed dosed reasons by race, 
the four ordinal categories were reclassified into two groups (never and rarely as one 
group; sometimes and always as the other).  The odds ratio was calculated to measure 
the strength of association between race and reasons for missed doses.  
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Table preparation and scrubbing of data was performed in SQL Server using SQL 
Management Studio.  Data was imported and statistical tests performed using SAS 
Enterprise. 
 
3.3.10 Sample Size and Power Calculations 
The following is an equation reduced from an exchangeable correlation matrix 
described and derived in detail in Liu and Liang’s 1997 Biometrics paper.[14]  This equation 
is useful for calculating sample sizes and power for correlated observations in longitudinal 
studies: 
 
𝑚 =
(𝑧1−∝/2 + 𝑧1−𝛽)
2
(𝜋1𝑝𝑜(1 − 𝑝𝑜) + 𝜋0𝑝1(1 − 𝑝1))(1 + (𝑛 − 1)𝜌)
𝑛𝜋0𝜋1(𝑝1 − 𝑝𝑜)2
 
 
The table below displays the sample sizes needed to detect a difference as 
specified between p0 and p1 with p0 reflecting the prevalence of the response  (e.g. 
virologic failure)  in the referent group and p1 reflecting the prevalence of the response 
in the comparison group.  Multiple scenarios for 𝜌 (0.2, 0.5, 0.8) are shown to reflect the 
within-group correlation of the repeated measure of interest for each aim.  For 
example, in the first row for Aim 2a, a minimum total sample size of 428 (219 per group) 
is needed to detect a difference (p0=0.20 and p1=0.30) assuming a 5% significance, 
𝜌=0.2, and achieving 80% power.  
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Table 1 
Sample Size Calculation for Correlated Observations 
 N p0 p1   M 
Sample size 
total 
Difference Comment 
0.2 3 0.20 0.30 0.5 0.5 214.11 428 10% 
Aim 2a, VF (AA vs EA), 
good adherers 
0.5 3 0.20 0.30 0.5 0.5 305.87 612 10% 
Aim 2a, VF (AA vs EA), 
good adherers 
0.8 3 0.20 0.30 0.5 0.5 397.63 795 10% 
Aim 2a, VF (AA vs EA), 
good adherers 
0.2 3 0.35 0.45 0.5 0.5 274.87 550 10% 
Aim 2a, VF (AA vs EA), 
poor adherers 
0.5 3 0.35 0.45 0.5 0.5 392.67 785 10% 
Aim 2a, VF (AA vs EA), 
poor adherers 
0.8 3 0.35 0.45 0.5 0.5 510.47 1021 10% 
Aim 2a, VF (AA vs EA), 
poor adherers 
0.2 10 0.85 0.75 0.5 0.5 109.37 328 -10% 
Aim 2b, mild to 
CESD>=16 
0.5 10 0.85 0.75 0.5 0.5 214.83 645 -10% 
Aim 2b, mild to 
CESD>=16 
0.8 10 0.85 0.75 0.5 0.5 320.30 961 -10% 
Aim 2b, mild to 
CESD>=16 
 
 
 
3.4 Results 
Figures 1 and 2 describe the demographic characteristics of the self-report 
population by race and depressive symptoms categories.  Study participants were 
classified as either African American (AA), European American (EA), Hispanic, or Other.  
Study participants were classified (using the CES-D cutoff of 16) at baseline as either 
“Major Depressive Symptoms” or “Mild Depressive Symptoms”.  The subpopulations 
between AA and EA were similar at baseline with the exception of rank with EA having a 
much higher proportion of participants with the rank of an officer than for AA (16.7% vs 
4.9%).  Conversely, AA had a larger proportion of enlisted (86.5%) than for EA (69.5%).  
EA tended to be in cohabitated relationships (36.9% vs 25.9%). While nadir cd4 was 
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lower for AA (237 counts/mm3 versus 246 counts/mm3 for EA), it was not appreciably 
different. 
Similarly when examining the characteristics of the population by CES-D (< 16 vs 
>=16), participants were generally comparable with slightly more females observed in 
>=16 (depressive symptoms) group (7.6% vs 6.0%).  Race and rank were relatively even, 
with slightly higher percentage of individuals at baseline (< 16) who were active duty, 
cohabitating, and elevated nadir cd4 at 250 counts/mm3 (versus 236 counts/mm3).       
 
Race (African 
American) 
Total 
(n=653) 
 Race (European 
American) 
Total 
(n=676) 
           
Demographics (at 
baseline) 
  Demographics (at 
baseline) 
 
 Age   34 years   Age   33 years 
 Gender     Gender   
  Female  51 (7.8%)    Female  34 (5.0%) 
  Male  602 (92.2%)    Male  642 (95.0%) 
 Rank (at Baseline)     Rank (at Baseline)  
  Enlisted  565 (86.5%)    Enlisted  470 (69.5%) 
  Officer  32 (4.9%)    Officer  113 (16.7%) 
  Warrant  3 (0.46%)    Warrant  5 (0.7%) 
  Unknown  53 (4.9%)    Unknown  88 (13%) 
 Marital Status 
(Current) 
   Marital Status 
(Current) 
 
  Cohabitating  169 (25.9%)    Cohabitating  246 (36.4%) 
  Single  353 (54.1%)    Single  388 (50.0%) 
  Separated  98 (15.0%)    Separated  76 (11.2%) 
  Unknown  53 (8.1%)    Unknown         16 (2.4%) 
 Duty Status (at 
Baseline) 
   Duty Status (at 
Baseline) 
 
  Active Duty  459 (70.3%)    Active Duty 456 (67.5%) 
  Dependent  28 (4.3%)    Dependent 29 (4.3%) 
  Other  63 (9.7%)    Other  62 (9.2%) 
  Retired  103 (15.8%)    Retired  129 (19.1%) 
 Nadir_CD4  237 
(counts/mm3) 
  Nadir_CD4  246 
(counts/mm3) 
Figure 1 – Demographics of Self-Report by Race (AA vs EA) 
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CES-D (< 16) Minor Dep. 
Total 
(n=681) 
   
CES-D (>= 16) Major Dep. 
Total 
(n=818) 
 
Demographics (at 
baseline) 
  Demographics (at 
baseline) 
 
 Age   33 years   Age   34 years 
 Gender     Gender   
  Female  41 (6.0%)    Female  62 (7.6%) 
  Male  640 (94.0%)    Male  756 (92.4%) 
 Race/Ethnicity     Race/Ethnicity   
  Black  277 (40.7%)    Black  340 (41.6%) 
  Hispanic          55 (8.1%)    Hispanic  86 (10.5%) 
  Other  35 (5.2%)    Other  55 (6.7%) 
  White  314 (46.1%)    White  337 (41.2%) 
 Rank (at Baseline)     Rank (at Baseline)  
  Enlisted  520 (76.4%)    Enlisted  636 (77.8%) 
  Officer  78 (11.4%)    Officer  77 (9.4%) 
  Warrant  6 (0.9%)    Warrant  3 (0.4%) 
  Unknown  77 (11.3%)    Unknown  102 (12.5%) 
 Marital Status 
(Current) 
   Marital Status 
(Current) 
 
  Cohabitating  231 (33.9%)    Cohabitating  236 (28.8%) 
  Single  349 (51.2%)    Single  435 (53.2%) 
  Separated  80 (11.8%)    Separated  112 (13.7%) 
  Unknown  21 (3.1%)    Unknown  35 (4.3%) 
 Duty Status (at 
Baseline) 
   Duty Status (at 
Baseline) 
 
  Active Duty  490 (72.0%)    Active Duty 531 (64.9%) 
  Dependent  30 (4.4%)    Dependent 45 (5.5%) 
  Other  59 (8.7%)    Other  79 (9.7%) 
  Retired  102 (15.0%)    Retired  163 (19.9%) 
 Nadir_CD4  250 
(counts/mm3) 
  Nadir_CD4  236 
(counts/mm3) 
Figure 2 – Demographics of Self-Report by CES-D score (<16  vs >=16) at baseline 
 
 
To better assess adherence rates by race and depressive symptoms, the mean 
adherence rate was calculated at the individual and by race/ethnicity group level.  Overall 
mean depressive symptom score was calculated based on all available CES-D scores from 
past visits during the entire study period.  The proportion of individuals with overall mean 
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adherence within the optimal adherence group cutoff (>=90%) is shown in Figures 3 and 4.  
A higher proportion of EAs (92.6%) had an overall mean adherence at or above the optimal 
adherence cutoff of 90%.  Conversely, AAs had only 85.7% of individuals with overall mean 
adherence at or above the cutoff.  Those who had no or minor depressed symptoms (< 16) 
had 91.6% of individuals within their group at or above the cutoff.  Those with depressive 
symptoms (>=16) reported only 87.6% of participants at or above the 90% optimal cutoff.  
 
 
Self-Reported Adh (Race = AA) 
 
Self-Reported Adh (Race = EA) 
(Mean) Adh Freq Percent 
 
(Mean) Adh Freq Percent 
Adh>=0-30 2 0.32% 
 
Adh>=0-30 2 0.31% 
Adh>=30-60 11 1.78% 
 
Adh>=30-60 4 0.61% 
Adh>=60-90 75 12.16% 
 
Adh>=60-90 42 6.45% 
Adh>=90 529 85.74% 
 
Adh>=90 603 92.63% 
Total 617 100% 
 
Total 651 100% 
       Self-Reported Adh (Hispanic) 
 
Self-Reported Adh (Other) 
(Mean) Adh Freq Percent 
 
(Mean) Adh Freq Percent 
Adh>=0-30 0 0.00% 
 
Adh>=0-30 0 0.00% 
Adh>=30-60 3 2.13% 
 
Adh>=30-60 2 2.22% 
Adh>=60-90 9 6.38% 
 
Adh>=60-90 9 10.00% 
Adh>=90 129 91.49% 
 
Adh>=90 79 87.78% 
Total 141 100% 
 
Total 90 100% 
Figure 3 – Overall Mean Adherence by Race/Ethnicity 
 
 
 
Self-Reported Adh (CESD<16) 
 
Self-Reported Adh (CESD<16) 
(Mean) Adh Freq Percent 
 
(Mean) Adh Freq Percent 
Adh>=0-30 2 0.21% 
 
Adh>=0-30 3 0.28% 
Adh>=30-60 6 0.62% 
 
Adh>=30-60 16 1.51% 
Adh>=60-90 73 7.53% 
 
Adh>=60-90 112 10.59% 
Adh>=90 888 91.64% 
 
Adh>=90 927 87.62% 
Total 969 
  
Total 1058 
  Figure 4 – Overall Mean Adherence by CESD 
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Adherence over time (Race = AA) 
                 
  1 2 3 4 5 6 7 8 9 10 Total 
Adh Catg             
 >=0-30 Freq 6 3 5 1 2 3 0 1 2 0 23 
 Col Pct 0.92 0.78 1.34 0.29 0.64 0.98 0 0.44 1.59 0  
 >=30-60 Freq 16 2 6 1 1 4 1 4 3 0 38 
 Col Pct 2.45 0.52 1.61 0.29 0.32 1.31 0.35 1.76 2.38 0  
 >=60-90 Freq 59 35 30 29 17 26 19 11 8 0 234 
 Col Pct 9.02 9.04 8.04 8.45 5.47 8.52 6.67 4.85 6.35 0  
 >=90 Freq 572 347 332 312 291 272 265 211 113 5 2720 
 Col Pct 87.6 89.66 89.01 90.96 93.57 89.18 92.98 92.95 89.68 100  
Total Freq 653 387 373 343 311 305 285 227 126 5 3015 
 Percent 21.66 12.83 12.37 11.37 10.31 10.11 9.45 7.53 4.18 0.17 100 
Figure 5a – Adherence over time (Race = AA) 
 
 
Adherence to HIV medication is important not only for the newly diagnosed 
individuals during initiation of HAART, but over time for the duration of the disease.  In 
Figure 5a (read column percent), the proportion of AA study participants who had optimal 
adherence >90% ranged from a starting point of 87.7% to high of 93.6%.  Trending appeared 
to be heading in a positive manner.  In Fig 5b, when comparing to EAs, the proportion of EA 
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with optimal adherence stayed consistently in the mid-90 percentiles.  The trend over time 
remained relatively flat. 
 
 
Adherence over time (Race = EA) 
                      
Figure 5b – Adherence over time (Race = EA) 
  
 
In Figure 5c, the highly adherent subsets of AA and EA were analyzed alone in the 
same chart to better distinguish the spread (difference in adherence rates) between the 
two groups over time.  From the figure below, while the adherence rate gap varied between 
AA and EA over time, it continued to persist showing EA consistently having a higher mean 
adherence percentage over AA.  Similarly, highly adherent subsets of those who are mildly 
  1 2 3 4 5 6 7 8 9 10 Total 
Adh Catg  
           >=0-30 Freq 7 3 1 2 4 3 0 1 1 0 22 
 Col Pct 1.04 0.66 0.23 0.52 1.1 0.88 0 0.44 0.65 0  
 >=30-60 Freq 3 4 1 3 4 3 2 1 0 0 21 
 Col Pct 0.44 0.88 0.23 0.77 1.1 0.88 0.64 0.44 0 0  
>=60-90 Freq 25 18 15 16 7 13 12 9 6 1 122 
 Col Pct 3.7 3.96 3.51 4.12 1.93 3.82 3.83 4 3.9 7.69  
>=90 Freq 641 430 410 367 347 321 299 214 147 12 3188 
 Col Pct 94.82 94.51 96.02 94.59 95.86 94.41 95.53 95.11 95.45 92.31  
Total Freq 676 455 427 388 362 340 313 225 154 13 3353 
 Percent 20.16 13.57 12.73 11.57 10.8 10.14 9.33 6.71 4.59 0.39 100 
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or have no depressive symptoms (<16) were compared to those with depressive symptoms 
(>=16) over time.  Those with depressive symptoms (>=16) remain in the upper 80th and low 
90th percentiles.  The chart also showed a noticeable gap between the (< 16) and (>=16) 
groups that persisted over time. 
   
 
 
Adherence by Race    Adherence by CESD 
 
  1 2 3 4 5 6 7 8 9 10 Total 
Adh Catg 
>=90 
            
EA Freq 641 430 410 367 347 321 299 214 147 12 3188 
 Col 
Pct 
94.82 94.51 96.02 94.59 95.86 94.41 95.53 95.11 95.45 92.31  
AA Freq 572 347 332 312 291 272 265 211 113 5 2720 
 Col 
Pct 
87.6 89.66 89.01 90.96 93.57 89.18 92.98 92.95 89.68 100  
CESD < 16 Freq 573 137 295 196 253 199 189 140 55 10 2047 
 Col 
Pct 
93.93 97.86 94.25 95.61 95.11 93.43 95.45 95.89 96.49 100   
CESD >= 16 Freq 642 152 317 166 231 185 215 155 46 8 2117 
 Col 
Pct 
88.07 91.57 90.57 87.37 91.3 89.81 91.49 91.18 95.83 88.89  
FIgure 5c – Highly Adherent (>=90) by Race and by CESD score  
 
 
3.4.1 Assessing Relationship Between Race and Depressive Symptoms 
A contingency table was produced (figure 6) to assess the relationship between race 
and depressive symptoms within the NHS self-report sub population.  The continency table 
revealed whether there were strata level differences between the two variables.  The 
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percentages of AA and EA with no or mild depressive symptoms (< 16) were similar (47.3% 
versus 49.2%).  This also meant that the percentage of depressed individuals would be close 
(52.7% versus 50.9%).  From this crude table, no association was observed between AA/EA 
and CES-D scores. 
 
 
  
Race/Ethnicity 
 
CES-D 
 
AA EA Hispanic Other Total 
< 16 Freq 867 1009 179 103 2158 
 
Col Pct 47.33 49.22 44.09 45.58 
 
>= 16 Freq 965 1041 227 123 2356 
 
Col Pct 52.67 50.78 55.91 54.42 
 
Total Freq 1832 2050 406 226 4514 
Figure 6 – Contingency table between Race/Ethnicity and CES-D score 
 
 
 
3.4.2 Evaluating Association Between Adherence and HIV Disease Indicators While 
Adjusting for Race and Depressive Symptoms in Repeated Measures Analysis 
 
In conducting the primary analysis of evaluating self-reported adherence and its 
association with HIV indicators (viral load and CD4 counts), CES-D was included in the 
original model that was analyzed for aim 1.  CES-D was treated categorically as the <16 
and >=16 groups have historical and practical utility in classifying those with major vs 
minor depressive symptoms.  As a precaution, an interaction term for race_ethnicity 
and CES-D score was included in the final model.  As is shown in figure 7, self-reported 
adherence continued to be negatively associated with an increase in log10 viral load.  
The coefficient estimate -.01 was slightly less attenuated than the estimate from the 
original model without CES-D (-.014).  However, the effect was highly significant at 
p<.0001 nonetheless.  Race, AA specifically, continued to demonstrate an independent 
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association with viral load with a coefficient estimate of 0.11 log10 viral load greater 
than EA keeping all reference groups and covariates constant.  CES-D score was found 
not to be significant nor were any of the interaction terms.  
 
 
Fig 7 - Mixed Effect Final Model – Viral Load (Includes Race*CESD Interaction Term) 
Effect Values Estimate 
  Standard  
Error 
Pr > |t| 
Intercept 
 
3.55 0.10 <.0001 
Self-Reported Adh 
 
-0.01 0.0008 <.0001 
Followup Period 
 
-0.04 0.003 <.0001 
Race_Ethnicity Black 0.11 0.03 0.0008 
 Hispanic 0.02 0.06 0.7160 
 Other 0.01 0.07 0.8703 
 White 0.00 . . 
Rank Enlisted 0.08 0.04 0.0478 
 
Unknown 0.03 0.05 0.6076 
 
Warrant -0.06 0.17 0.7225 
 
z_Officer 0.00 . . 
Nadir CD4 per 50 cells 
 
-0.04 0.004 <.0001 
Hep C Coinfection 
 
0.11 0.05 0.0153 
Proximity to clinic Far -0.04 0.04 0.2493 
 
Moderate 0.06 0.03 0.0578 
 
Near 0.00 . . 
CES-D score >=16 -0.02 0.03 0.3920 
 
< 16 0.00 . . 
Race*CES-D_AA >=16 0.06 0.04 0.1197 
 
< 16 0.00 . . 
Race*CES-D_Hispanic >=16 0.13 0.07 0.0654 
 
< 16 0.00 . . 
Race*CES-D_Other >=16 0.05 0.09 0.6025 
 
< 16 0.00 . . 
 
 
For the mixed effect model with CD4 count as the outcome variable as shown in 
figure 8, self-reported adherence was shown to be positively associated with CD4 count 
at 0.80 cells/mm3 per percentage increase in adherence.  It could also have been stated 
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that for every 10% increase in adherence, there is an 8.0 cells/mm3 increase in CD4 
count.  As was observed in the viral load model, race/ethnicity continued to 
demonstrate an independent effect on outcomes even after adjustment of known risk 
factors.  AA was negatively associated with CD4 count with a coefficient estimate of -
16.58 cells/mm3 (when compared to EA and keeping other covariates constant).  
Interestingly, the “other” category in race had the largest coefficient estimate (-75.96) 
that was highly significant at p=0.0058.  CES-D score was marginally non-significant for 
those who were depressed (16.29) and an interaction term between CES_D and AA was 
detected with coefficient of 35.5 and significant at p=0.0046 suggesting potential effect 
modification.      
 
 
Fig 8 - Mixed Effect Final Model – CD4 (Includes Race*CESD Interaction Term) 
 
Effect Values Estimate 
  Standard  
Error 
Pr > |t| 
Intercept 
 
236.09 31.47 <.0001 
Self-Reported Adh 
 
0.80 0.25 0.0014 
Followup Period 
 
13.56 0.89 <.0001 
Rank Enlisted -38.45 18.51 0.038 
 
Unknown 8.20 23.75 0.7298 
 
Warrant -32.71 73.73 0.6573 
 
Officer 0.00 . . 
Race_Ethnicity Black -16.58 13.65 0.2247 
 
Hispanic -19.26 22.28 0.3875 
 
Other -75.96 27.52 0.0058 
 
White 0.00 . . 
Nadir CD4 per 50 cells 
 
54.55 1.94 <.0001 
CES-D score >=16 16.29 8.47 0.0545 
 
< 16 0.00 . . 
Race*CES-D_AA >=16 -35.50 12.53 0.0046 
 
< 16 0.00 . . 
Race*CES-D_Hispanic >=16 -10.48 21.60 0.6278 
91 
 
 
< 16 0.00 . . 
Race*CES-D_Other >=16 -20.11 27.65 0.4672 
 
< 16 0.00 . . 
 
 
 
3.4.3 Reasons for Missed Doses (Nonadherence Factors) by Race 
For each of the 13 factors (data for one missing dose reason, alcohol was not 
provided in data set), responses were stratified by race.    In figure 9, one of the reasons 
for missed doses, ‘OTHERS NOTICE’ is shown as an example of the stratification output.  
The vast majority of responses (93.2%) reported that missed doses due to others notice 
(i.e. concern of others noticing them taking medication) was not an issue.  However, of 
those that reported that “others notice” was sometimes or often the reason for missing 
taking medications, 72.5% of the 131 (Sometimes) reported instances were made by an 
AA.  Similarly, 81% of the 42 (Always) instances were reported by an AA.  
 
 
  OTHERS NOTICE   
  AA EA  
Never Freq 2962 3431 6393 
1 Percent 43.42 50.3 93.73 
 Row Pct 46.33 53.67  
 Col Pct 91.17 96.05  
Rarely Freq 158 97 255 
2 Percent 2.32 1.42 3.74 
 Row Pct 61.96 38.04  
 Col Pct 4.86 2.72  
Sometimes Freq 95 36 131 
3 Percent 1.39 0.53 1.92 
 Row Pct 72.52 27.48  
 Col Pct 2.92 1.01  
Always Freq 34 8 42 
4 Percent 0.5 0.12 0.62 
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 Row Pct 80.95 19.05  
 Col Pct 1.05 0.22  
  3249 3572 6821 
 Frequency Missing = 52   
Figure 9 – Example of Reason for Missed Dose Stratified by Race (AA vs EA) 
 
 
 
To better assess the differences in response between AA and EA for the various 
reasons/factors, the never and rarely responses were collapsed into the “no issues” 
group and the sometimes and always responses categorized into the “issues” group.  
Table 1 provides a summary of all 13 factors and their corresponding response rates by 
race.  The overall percent represents the percent of total visits where the reason of 
interest was identified as the “issue” or factor for the missed dose.  For example, 
“Depressed” was identified in 3.11% of all visits as sometimes or often the reason for a 
missed dose(s).  AA% and EA% reflects the proportion of visits reported as an issue by 
their respective race.  Value and Prob were related to the chi square statistic that was 
implemented to test the independence between race/ethnicity and the factor/reason of 
interest.  Additionally, the odds ratio was calculated to quantify the strength of 
association between race and reason for missed dose. 
  
As shown in table 2, the top two commonly identified factors reported as 
sometimes or often the reasons for missed doses were Routine Change and Forgot with 
17.26% and 13.3% overall respectively.  The chi square statistic was not significant at 
p<.05 for Forgot which indicated that the association between race and this particular 
factor was not significant.  The OR of 1.09 confirmed that race was not likely related to 
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the issue of forgetting to take meds.  Conversely, Others Notice, while only representing 
2.54% of overall visits, the OR=3.33 indicated that AA were over three times as likely 
than EA to report missing doses due to concern/stigma of others noticing them take 
their medication.       
 
Table 2 - Missed Dose Reason Response Rate by Race (2006-2010 total visits by AA or 
EA) 
 
Reason 
Overall%* 
(n=6873) 
AA% 
(n=3275) 
EA% 
(n=3598) 
Value**** Prob OR 
Others Notice 2.54% 4 1.2 51.62 <.0001 3.33 
Depressed 3.11% 4.3 2 28.16 <.0001 2.15 
Don’t Feel Like 5.30% 7.3 3.4 51.42 <.0001 2.15 
Felt Toxic 2.07% 2.8 1.4 15.12 0.0001 2.00 
Side Effects 4.20% 5.7 2.9 31.02 <.0001 1.97 
Sleep 9.84% 13.2 6.8 79.15 <.0001 1.94 
Too Many 2.05% 2.7 1.4 14.56 0.0001 1.93 
Ran Out 5.00% 6.2 4 16.70 <.0001 1.55 
Hard Instructions 2.24% 2.7 1.8 7.01 0.0081 1.50 
Sick 2.80% 3.3 2.4 4.81 0.0283 1.38 
Routine Change 17.26% 18.7 15.9 9.18 0.0025 1.18 
Other Reason 2.20% 2.3 2.11 0.26 0.6073 1.09 
Forgot 13.30% 13.7 12.9 0.95 0.3285 1.06 
*Percent of visits where reason response was "sometimes" or "often" 
   **Percent among AA visits  where response was "sometimes" or "often" 
  ***Percent among EA visits  where response was "sometimes" or "often" 
  ****Chi Square test to test association between race/ethnicity and respective reason/factor 
  
We examined response rates among those at high risk for missed doses.  We did 
so by excluding the records of those visits where the participant explicitly reported no 
adherence issues in the past two weeks (missed doses = 0).  By excluding records where 
the self-reported number of missed doses was zero, the remaining subset contained a 
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majority of records with participant reported number of missed doses.  The 
stratification procedures and statistical tests employed to produce table 1 was repeated 
for this high risk subset.  Table 3 reflects the reasons for missed doses among those 
visits that had likely reported missed doses.     
 
 
Table 3 - Missed Dose Reason Response Rate by Race (among visits likely to have a 
reported missed dose) 
 
Reason 
Overall%* 
(n=1996) 
AA%**  
(n=1118) 
EA%***  
(n=878) 
Value**** Prob OR 
Others Notice 6.8 9.5 3.3 29.04 <.0001 2.88 
Felt Toxic 5.3 7.0 3.1 14.30 0.0002 2.26 
Too Many 4.7 6.2 2.9 11.56 0.0007 2.14 
Side Effects 10.2 13.2 6.3 25.42 <.0001 2.10 
Depressed 7.9 10.0 5.3 14.87 0.0001 1.89 
Don’t Feel Like 13.2 16.7 8.9 25.64 <.0001 1.88 
Hard Instructions 5.0 6.2 3.6 7.15 0.0075 1.72 
Sleep 22.4 27.5 16.0 37.06 <.0001 1.72 
Ran Out 11.0 12.4 9.2 4.98 0.0256 1.35 
Sick 6.6 7.4 5.6 2.41 0.1205 1.32 
Routine Change 35.5 36.9 33.8 2.02 0.1554 1.09 
Other Reason 5.3 5.2 5.6 0.14 0.7112 0.93 
Forgot 30.4 28.8 32.4 3.01 0.0827 0.89 
*Percent of visits where doses missed was reported other than 0 and response was "sometimes" or "often" 
**Percent among AA visits where reported value other than 0 and response was "sometimes" or "often  
***Percent among EA visits where reported value other than 0 and response was "sometimes" or "often  
****Chi Square test to test association between race/ethnicity and respective reason/factor 
  
By limiting the records to the high risk subset, the overall, AA, and EA 
percentages all increased as expected.  Routine Change and Forgot continued to 
represent the top two reasons for missed doses.  However, in this subset, chi-square 
statistic was not significant for both reasons (in the previous table, Routine Change was 
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significant).  This means that race was not associated with the Forgot and Routine 
Change factors.  Similar to table 2, the vast majority of reasons (9/13 or 69.2%) were 
reported on average more by AA than by EA.    
 
3.5 Discussion 
In this aim, we described and evaluated the relationship between race/ethnicity 
and adherence, depressive symptoms and adherence, and their role as mediating 
factors in the association between medication adherence and HIV disease indicators 
(change to viral load and cd4 counts).  In addition, we described the responses for 13 
self-reported “reasons” for missed medication doses (nonadherence factors) and 
identified the “reasons” that differed by race (AA vs EA).  A smaller, high risk subset was 
created and similarly analyzed to detect possible variation in responses by race.  
 
 Self-Reported Adherence by race/ethnicity was shown to be higher in EA overall 
with 92.6% of participants with mean adherences at or above the optimal adherence 
level (>=90%).  AA showed a lower rate with 85.7% of participants with mean 
adherences at or above the optimal adherence level (>=90%).   
  
Adherence by depressive symptoms category was shown to be higher for those 
with CES-D score < 16 (minor or no depressive symptoms) with 91.6% of participants 
with mean adherences at or above the optimal adherence level (>=90%) whereas 87.6 
participants from the  CES-D score >= 16 (major depressive symptoms) group having 
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mean adherence at the optimal adherence level (>=90%).  Wagner, et al. using the same 
optimal adherence cutoff level of (>=90%) and also relying upon self-report adherence 
reported a mean of 69% at baseline.[9]  Self-reported adherence has been known to 
overestimate true adherence due to recall and social desirability bias.  It is more than 
likely that true adherence for both CES-D< 16 and CES-D>=16 groups are lower.  
Nonetheless, the reported lower adherence score among the CES-D>=16 group is 
consistent with previous studies indicating depression’s role in lowering adherence.[5, 
15-17]  
 
In regards to adherence over time, self-reported adherence for AA ranged from 
as low as 87.7% to a high of 93.6% from 2006-2010 with increasing trend over time 
while EA maintained adherence levels in the mid-90s (plateau) for the duration of the 
study.  For CES-D >=16, the low end begin at 88.07% to a high of 95.83%.  For CES-D < 
16, the low was 93.93% and held relatively steady 96.49%.  CES-D<16 group also 
reported a higher adherence rate at each of the 10 time points.       
 
While not the primary focus of this study, the relationship between race and 
depression was examined in a contingency table analysis.  AA and EA did not differ much 
from one another with both groups with slightly over half (50.8% and 52.7% 
respectively) scoring >=16.  This was performed to test for potential effect modification. 
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In the final mixed effect model, race was shown to be a significant predictor in 
influencing the association between self-reported adherence and viral load.  Race, 
specifically AA, was consistently significant as an independent predictor with coefficient 
estimate -.01 log10 viral load.  While a small effect, it was still highly significant at 
p<.0001.  In regards to immunological outcomes, race (AA) was significant with 
coefficient estimate of -16.58 cells/mm3 (when compared to EA and keeping all other 
covariates constant).  For both HIV outcomes, the difference in effect size when 
comparing race (AA vs EA) is small, but consistently significant even after accounting for 
all other covariates. 
  
In the last analysis step examining the reasons for missed doses, forgot and 
routine change were the top 2 reasons identified by participants.  This is consistent with 
the literature as forgetting to take doses appears to be a very common issue.  While the 
remaining reasons were not as common, the differences between AA and EA in 
reporting these was valid enough to see a trend (of 13 total variables, 11 were instances 
where AA had higher rate on average compared to EA (see tables 1 and 2).  There were 
a number of reasons (e.g. Others Notice, Sleep, Depressed, Don’t Feel Like (taking 
meds), etc.) that could be investigated further.   
  
This study has a number of limitations.  First, self-reported adherence is known 
to be overestimated and may have inflated true adherence rates.  However, even if 
inflated, as long as inflation occurs randomly (nondifferential) for both races, any 
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difference between races (AA and EA) should still be detected.  Diagnosed clinical 
depression or other medical records (to diagnose similar conditions dysthymia) would 
have been ideal to help exclude those with previous depression and to help confirm 
depression status.  Also related is the fact that we did not have access to 
antidepressants, SSRIs, etc.  Individuals on and adherent to antidepressants have been 
shown to be adherent to other medications including HAART.[10]  Fortunately, as 
depression was not the primary exposure and we had multiple events over time 
(repeated measures), measuring depressive symptoms as a surrogate seemed 
appropriate.  Plus, if someone was adherent to SSRI and did not exhibit depressive 
symptoms, theoretically that individual would likely be adherent to HAART and have 
improved outcomes.  Other limitations as discussed in the first aim would continue to 
apply to the same data and/or methodology brought over (categorization of certain 
covariates, etc.) 
  
In conclusion, while the effect sizes were small, the effect of race (AA) on HIV 
indicators (repeated measures), adherence (over time), and being associated with the 
majority of the reasons for missed doses compared to EA is significant and gives 
credence to further research needing to be done to identify and test new explanations 
for these differences. 
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4. DISCUSSION and RECOMMENDATIONS/FUTURE DIRECTION 
Adherence to antiretroviral therapy is a critical factor in improving HIV outcomes 
and quality of life for those already infected with HIV while simultaneously preventing 
transmission to new  at risk populations.  Despite the advances made in antiretroviral 
therapy, subsets of the HIV population are  undiagnosed, aware of their HIV status but 
not actively engaged with their care, and/or insufficiently using antiretroviral therapy.[1]  
Nonadherence continues to be a major challenge to address as the issues are 
multifactorial.[2]  Many studies examining HIV outcomes, race/ethnicity differences, 
and HAART initiation among the US Military Natural History Study (NHS) have identified 
adherence as an important factor to research further in current and future studies.[3-5]  
Thus, this dissertation can be broken into three major focus areas on adherence: 
Measurement, Gaps/Disparities, and finally Barriers Analysis.  The aims of this 
dissertation can be classified with each focus area as follows: 
 
Measurement: AIM 1 - Develop and compare three adherence measures (self-reported, 
PDC clinical, PDC single drug).  Assess how each measure performs by comparing results 
to one another and how it is associated with HIV indicators (viral load, and CD4). 
 
Gaps/Disparities: AIM 2a and 2b- Assess impact of racial differences and depressive 
symptoms in adherence and virological outcomes.   
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Barriers Analysis: AIM 2a - Examine reasons for missed doses and describe differences 
by race. 
 
In Chapter 1, we described in detail the number of adherence methods available 
with particular interest given to self-report and pharmacy refill adherence.  Self-
reported adherence has traditionally been easier to administer, but historically 
overestimates adherence and is subject to recall and social desirability bias.  In regards 
to pharmacy refill, two measures were discussed: Medication Possession Ratio (MPR) 
and Proportion of Days Covered (PDC).  Although MPR has been utilized and referenced 
in the literature longer, adherence may be overestimated due to its reliance on days 
supply of medication.  Early pick up of a refill or switch to another medication during the 
interval of interest may artificially increase adherence scores.  PDC tends to be more 
conservative by focusing on the days covered by medication, rather than days supply.  
PDC has been endorsed as the measure of choice by the Pharmacy Quality Alliance 
(PQA).[6]. 
 
 In Chapter 2, we provided the details of implementing self-report and pharmacy 
refill measures (using PDC).  For pharmacy refill measures, leveraging the framework 
outlined by Leslie, et al., we created a pharmacy refill database to populate the 
antiretroviral pharmacy refill information into daily records per study participant.  Two 
pharmacy refill PDC measures were created, with one defining adherence as meeting a 
stringent set of clinical rules (PDCc) while the other defined PDCs requiring only 
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evidence of any single antiretroviral.  Adherence was defined in 6 month intervals, as 
every six-months study participants were scheduled for a follow up visit.  In addition, 
the interval needed to be long enough to actually detect nonadherent events as certain 
medications had days supply ranging as large as 90 – 120 days (too short of a period 
would assume 100% adherence).  Business rules to allow for exclusion of days from the 
denominator were discussed.  Mean adherence levels were categorized as follows: 
Adherent (>=90%), and non-adherent (>=0-30%, >=30-60%, >=60-90%,).  For self-report, 
we found that over 89% of study participants from 2006-2010 were considered optimal 
adherers (>=90%).  For pharmacy refill, using PDC clinical criteria, only 32% of 
participants from 2005-2009 were optimal adherers (>=90%) whereas for PDC single art 
criteria, 61% of participants met the optimal adherers criteria.   
 
To assess inter-rater agreement between the different measures, we identified a 
subset of individuals with adherence data from both self-report and pharm refill for the 
same six month interval timeframes.  We conducted the Cohen’s kappa statistic to test 
level of agreement between self-report vs the two PDC pharmacy refill measures.  The 
results indicated only slight level of agreement between self-report and PDC in detecting 
optimal adherers (>90%).  The coefficient for self-report vs PDCC was 0.046, SE:0.0075 
while self-report vs PDCS also indicated only slight agreement at 0.055, SE: 0.011.  These 
results are consistent with literature in that self-reported adherence tends to report 
higher percentages.  However, the lack of correlation between pharmacy refill and self-
report contrasts that with much of what has been found in the literature recognizing 
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that there are differences in terms of population, methodology used, follow up time 
measured, and other factors.  Amico, et al, also performed an analysis comparing 
another adherence measure against self-report VAS (see table 1).[7]  In our analysis, we 
used a similar 2x2 table format and >=90% adherence cutoff.  When we restructured our 
table (Figure 1b) to match Amico’s format, it became clear that concordance in finding 
optimal adherers (>=90%) for both self-report and PDC was consistent with what Amico 
found (49% vs 48%).  The area that concordance was weak in our study was the 
discordance between PDC<90% and self-report >=90% (44% for PDCc and 28% for 
PDCs).  This variation suggested some reliability, data, or methodologic issues in 
identifying the poor adherers of the NHS population.   
 
  
Table 1 – Concordance table from Amico, et al.[7] 
 
 
 
 
Figure 1a – Original Cohen’s Kappa analysis 
 
 Cohen's Kappa Agreement (Self Report vs PDCC)  Cohen's Kappa Agreement (Self Report vs 
PDCS) 
  Self Report     Self-Report  
  yes* No     yes* No  
PDCC yes* 2298 110 2408   yes* 3053 175 3228 
 No 2091 209 2300   no 1336 144 1480 
  4389 319 4708    4389 319 4708 
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 *assuming adherence >= 90%    *assuming adherence 
>= 90% 
 
 Cohen's Kappa Index: 0.0461 SE:0.0075   Cohen's Kappa Index: 
0.0547 
SE:0.011 
 
 
 
Figure 1b – Modified Cohen’s Kappa analysis 
  
Cohen's Kappa Agreement (Self Report vs 
PDCC) 
  
Cohen's Kappa Agreement (Self Report vs 
PDCS) 
  Self Report     Self-Report  
  <90% >=90%     <90% >=90%  
PDCC <90% 4% 44% 2408   <90% 3% 28% 3228 
 >=90% 2% 49% 2300   >=90% 4% 65% 1480 
  4389 319 4708    4389 319 4708 
           
 *assuming adherence >= 90%    *assuming adherence >= 90%  
 Cohen's Kappa Index: 0.0461 SE:0.0075   Cohen's Kappa Index: 0.0547 SE:0.011 
 
 
 
Besides describing the adherence patterns and performance of each measure, 
the other objective of aim 1 was to evaluate the association between each adherence 
measure and HIV indicators.  This was assessed in Chapter 2 in a few contributory ways.  
The first method was to produce crosstabs of categorical adherence and categorical viral 
load for each of the three measures.  For self-report, a dose-response like association 
was seen for viral suppression (<=50 copies) with adherence increasing steadily from 
>=0-30 (25%), >=30-60 (39.74%), >=60-90(56.8%), and finally >=90(84.82%).  In addition, 
proportion of virally suppressed observations 84.2% of the observations being assessed 
were virally suppressed.  This fell within the range of what has been observed in the 
literature. A similar type of response was observed, but in the opposite direction for 
viral load >=10000 copies: Adherence decreased steadily >=0-30=(42.86), >=30-
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60(25.64%), >=60-90(14.5%), and >=90(2%).  For both PDC clinical and PDC single drug, a 
dose response relationship was not seen between viral load and adherence.  The 
adherence percentages along the viral suppression (<=50 copies) row were relatively 
flat. 
 
 The second method in demonstrating the association between adherence and 
HIV indicators was through the use of a mixed effect model.  The mixed effect model 
accounted for change to repeated measures (HIV outcomes, adherence) longitudinally.  
After adjusting for known covariates, in the final model, the independent association 
between self-reported adherence and viral load was shown to be significant over time 
with a decrease of 0.14 log units in viral load for every 10% increase in adherence.  Liu, 
et al., also using a mixed effect model, reported after increasing percent adherence by 
10%, viral load decreases of 0.18, 0.3, 0.42, and 0.54 log units for 12, 24, 36, and 48 
weeks respectively.[8]  When running the mixed effect models using PDC, the 
association between adherence and viral load was not significant, most likely due to the 
misclassification issues described earlier. 
 
 In moving from measurement to gaps/disparity, the purpose of aim 2a and 2b 
was to assess impact of racial differences and depressive symptoms in adherence and 
virological outcomes.  First, for racial differences, a number of analytical tests were 
performed.  The results from Chapter 3 showed that self-reported adherence for AA was 
consistently lower than EA when examining adherence overall, over time, and through a 
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mixed effect model.  The mean adherence rate was calculated at the individual and by 
race/ethnicity group level.  Overall mean depressive symptom score was calculated 
based on all available CES-D scores from past visits during the entire study period.  The 
proportion of individuals with overall mean adherence within the optimal adherence 
group cutoff (>=90%) was graphed below in Figures 3 and 4.  A higher proportion of EAs 
(92.6%) had an overall mean adherence at or above the optimal adherence cutoff of 
90%.  Conversely, AAs had only 85.7% of individuals with overall mean adherence at or 
above the cutoff.  When considering CES-D, those with depressive symptoms (>=16) 
remained in the upper 80th and low 90th percentiles.  The chart also showed a 
noticeable gap between the (< 16) and (>=16) groups that persisted over time.  Even if 
self-report responses were considered overestimated, the difference in adherence 
levels over time for both race and depressive symptoms is noteworthy.  Oh , et al. 
similarly reported such gaps in adherence differences between AA and EA.     
 
 
Adherence by Race    Adherence by CESD 
 
 
  1 2 3 4 5 6 7 8 9 10 Total 
Adh Catg 
>=90 
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EA Freq 641 430 410 367 347 321 299 214 147 12 3188 
 Col 
Pct 
94.82 94.51 96.02 94.59 95.86 94.41 95.53 95.11 95.45 92.31  
AA Freq 572 347 332 312 291 272 265 211 113 5 2720 
 Col 
Pct 
87.6 89.66 89.01 90.96 93.57 89.18 92.98 92.95 89.68 100  
CESD < 16 Freq 573 137 295 196 253 199 189 140 55 10 2047 
 Col 
Pct 
93.93 97.86 94.25 95.61 95.11 93.43 95.45 95.89 96.49 100   
CESD >= 16 Freq 642 152 317 166 231 185 215 155 46 8 2117 
 Col 
Pct 
88.07 91.57 90.57 87.37 91.3 89.81 91.49 91.18 95.83 88.89  
Figure 2 – Adherence by Race and by CESD 
 
 
 
Ribaudo reported differences between AA and EA regarding virologic failure 
rates.[9]  And while Mugavero also noticed racial differences between AA and EA for 
virologic failure in his respective population, he took his analysis one step further by 
focusing on a specific underlying barrier/factor that could explain the reported outcome 
failure by race.  He theorized and demonstrated that missed appointments were one of 
the factors that contributed to poor HIV outcomes.[10]  In this study, the final analysis 
examined (continuation of aim 2a) - reasons for missed doses and differences in 
response by race.  In table 2, the study population represented was the subset that 
reported missing doses on the survey.  The fact that this subset responded to the missed 
dose question made them perhaps more likely to have responded about other barrier 
issues.  Table 2 lists the reasons and sorts them by OR (impact of AA race on a particular 
factor).   “Forgot” and “Routine Change” were the most commonly reported issues (30% 
and 35% respectively), however there were no racial disparities identified (no significant 
differences between AA% and EA% regarding forgetting to take meds).  This is 
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consistent with what has been found in other studies.[11]  Barfod, et al. and Chesney, et 
al. identified forgetfulness as the primary reason for nonadherence for both the good 
and poor adherers.[11, 12]  Overall, in our study, more AA than EA reported issues with 
specific factors (OR>1).  The top 5 issues reported with greatest disparity between AA 
and EA were “Others Notice”, “Felt Toxic”,  “Too Many”, and “Side Effects” and 
“Depressed” .  None of the five reasons were related to logistics, instructions, or routine 
changes.  All were associated with either stigma, adverse reactions to antiretrovirals, or 
mental health/psychosocial issues.  
 
Table 2 - Missed Dose Reason Response Rate by Race (among visits likely to have a 
reported missed dose) 
 
Reason 
Overall%* 
(n=1996) 
AA%**  
(n=1118) 
EA%***  
(n=878) 
Value**** Prob OR 
Others Notice 6.8 9.5 3.3 29.04 <.0001 2.88 
Felt Toxic 5.3 7.0 3.1 14.30 0.0002 2.26 
Too Many 4.7 6.2 2.9 11.56 0.0007 2.14 
Side Effects 10.2 13.2 6.3 25.42 <.0001 2.10 
Depressed 7.9 10.0 5.3 14.87 0.0001 1.89 
Don’t Feel Like 13.2 16.7 8.9 25.64 <.0001 1.88 
Hard Instructions 5.0 6.2 3.6 7.15 0.0075 1.72 
Sleep 22.4 27.5 16.0 37.06 <.0001 1.72 
Ran Out 11.0 12.4 9.2 4.98 0.0256 1.35 
Sick 6.6 7.4 5.6 2.41 0.1205 1.32 
Routine Change 35.5 36.9 33.8 2.02 0.1554 1.09 
Other Reason 5.3 5.2 5.6 0.14 0.7112 0.93 
Forgot 30.4 28.8 32.4 3.01 0.0827 0.89 
*Percent of visits where doses missed was reported other than 0 and response was 
"sometimes" or "often" 
**Percent among AA visits where reported value other than 0 and response was 
"sometimes" or "often  
***Percent among EA visits where reported value other than 0 and response was 
"sometimes" or "often  
****Chi Square test to test association between race/ethnicity and respective 
reason/factor 
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4.1 Public Health Implication 
 Our findings on the adherence patterns among a longitudinal cohort (NHS) 
contribute to the body of existing adherence knowledge/research.  Recognizing that 
additional adjustments are needed (i.e. modification to business rules and exclusionary 
criteria), the development of an adherence database to capture daily records of 
adherence is a useful tool to monitor, predict, and analyze adherence rates within the 
NHS cohort.  However, additional work is needed before pharmacy refill adherence as it 
is currently is constructed can be operationalized.  Self-report adherence with VAS 
continues to be a useful, pragmatic means of measuring adherence and to obtain 
qualitative feedback from patients/participants.  Unlike the majority of adherence 
studies, adherence trends can be analyzed for longer durations (months, six month 
intervals, years, etc.).  We detected an independent association between race/ethnicity 
and HIV indicators in our mixed effect models.  As with most race studies, simply 
identifying factors that are statistically different between races, is informative, but not 
necessarily useful as often there are underlying factors/barriers that require further 
investigation.  We analyzed self-report data about reasons for missed doses.  We 
identified racial differences between certain factors (others notice, felt toxic, too many, 
side effects) that may warrant additional investigation.    
 
4.2 Recommendations and Future Directions 
 We developed an initial framework for measuring pharmacy refill adherence, but 
additional work is needed to validate this approach and make adjustments as 
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appropriate.  In this study, we measured adherence in six month intervals for up to 5 
years and selected the last HIV disease indicator during each six month interval.  To 
improve this approach, some adherence time to event (HIV outcome) analyses could be 
designed to help better validate the adherence measure(s) in question and better 
estimate the correlation between the two.  The analysis on barriers identified some 
potential factors/areas of disparity between AA and EA responses.  Further work is 
needed to evaluate these reasons for missed doses in a formal way.  Adherence 
methods require further review and vetting.  Additional analysis is needed to determine 
sources of incomplete or inaccurate pharmacy refill data.  Validation studies and 
ongoing evaluation of these methods are vital to the success and utility of these 
adherence measures in clinical and public health practice. 
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Appendix 
 
A.1  Self-reported adherence question from NHS Case Report Form 
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A.2  CES-D questions from Case Report Form 
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A.3  Missing dose reason question from Case Report Form 
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